
Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate 
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects 
With Friedreich Ataxia
Study ID: [REMOVED]
Protocol Approve Date: 06 October 2017
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information ([COMPANY_003]) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 2, Randomized, Double -Blind, Placebo -Controlled, Parallel -Arm Study to Evaluate 
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK -831 in Adult 
Subjects With Friedreich Ataxia
Short Title: TAK -831 in Friedreich Ataxia
Sponsor: [COMPANY_005] Development Center Americas, Inc.
One [COMPANY_005] Parkway
Deerfield, IL [ZIP_CODE] 
Study Number: TAK -831-1501
IND Number: 132,[ADDRESS_95632] Number: Not Applicable
Compound: TAK -
831
Date: 06October 2017 Version Number: Amendment No. 
01
Amendment History: 
Date Amendment Number Amendment Type Region
[ADDRESS_95633] will be provided to each site.[COMPANY_005] Development Center Americas, Inc. (TDC Americas) sponsored investigators per United 
States (US) requirement s will be provided with emergency medical contact [CONTACT_87782].
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section 3.1and relevant guidelines 
provided to the site.
Contact [CONTACT_39764]/Role Contact
[CONTACT_87783](medical advice on protocol and study drug)
Responsible Medical Officer 
(carries overall responsibility for the conductof the study)
Property of [COMPANY_005]: For non-commerdu
mo the applicable Terms of Useer Uniteer Uni
n cards n cards
or assignassig
evant guint gu
actcttho[COMPANY_003]
TAK-[ADDRESS_95634] for the individual participants in accordance 
with the requirements of this study protoc ol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!All applicable laws and regulations, including, without limi tation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The electronic signatures of the responsible [COMPANY_005] medical officer (and other signatories, as listed 
below) are provided on the last page of this document.
Property of [COMPANY_005]: For non-combject to the applicable Terms of Usedance dance 
olidatedlidate
ta privacpriva
fficer (anicer (a
[COMPANY_003]
TAK -[ADDRESS_95635] igator’s Brochure, package 
insert and any  other product information provided by  [CONTACT_456]. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and w ell-being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws an d regul ations, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Dof this protocol .
Signature [CONTACT_87872] (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95636] of Abbreviat ions............................................................................................... 18
3.4 Corporate Identificat ion........................................................................................... 19
4.0 INTRODUCTION ......................................................................................................... 20
4.1 Backgrou nd............................................................................................................. 20
4.1.1 Study  Drug ......................................................................................................... 20
4.1.2 Friedreich Ataxia ............................................................................................... 20
4.1.3Nonclinical Background ..................................................................................... 21
4.1.4 Clinical Background .......................................................................................... 21
4.2 Rationale for the Proposed Study ............................................................................. 23
4.3 Benefit/Risk Profile .................................................................................................[ADDRESS_95637] Populat ion......................................... 31
6.2.2 Justification o f Dose ........................................................................................... 32
6.2.3 Justification o f Measurements ............................................................................ 33
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831- 1501 Page 6 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
[IP_ADDRESS] Primary Outcome M easure: 9- HPT ..........................................................33
[IP_ADDRESS] Secondary Outcome  Measure: .................................................................33
[IP_ADDRESS] Explor atory Outcome Measure s...............................................................35
6.3 Premature Termination or Suspen sion of Study or Study Site...................................36
6.3.1 Criteria for Pr emature Termination or Suspension of the Study ..........................36
6.3.2 Criteria for Premature Termination or Suspension of Study Sites .......................37
6.3.3 Procedures for Premature Termination or Suspension of the Study or the
Participation of Study Site(s)..............................................................................37
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS ..............[ADDRESS_95638] ......................................43
8.0 CLINICAL STUDY MATERIAL MANAGEMENT .....................................................44
8.1 Study Drug a nd Materials ........................................................................................44
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling .....................................44
[IP_ADDRESS] Study Dr ug ..............................................................................................44
[IP_ADDRESS] Sponsor-supplied Drug ............................................................................[ADDRESS_95639] orage ..............................................................45
8.4 Study Drug Blind Maintenance................................................................................458.5 Unblinding Procedure..............................................................................................458.6 Accountability and Destruction of Sponsor-Supplied Drugs .....................................46
9.0 STUDY PLAN ..............................................................................................................48
9.1 Study Procedures .....................................................................................................48
9.1.1 Informed Consent Procedure ..............................................................................48
[IP_ADDRESS]
9.1.2 Demographics, Medical History, and Medication History  Proce dure..................48
9.1.3 Phys ical Examination Procedure ........................................................................48
9.1.4 Weight, Hei ght, and BMI ...................................................................................49
9.1.5 Vital Sign P rocedure ..........................................................................................49
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use355
............[ADDRESS_95640]
9.19.1
CCI
TAK -831
Study No. TAK -831-1501 Page 7of 114
Protocol Incorporating Amendment No. 01 06October 2017
9.1.6 Other Safet y Measurements ............................................................................... 50
9.1.7 Primary and Secondary  Efficacy Measurements ................................................. 50
9.1.8 Docum entati on of  Conco mitant Medi cations...................................................... 51
9.1.9 Docum entati on of  Concurrent Medi cal Condit ions............................................. 51
9.1.10 Procedures for Clinical Laboratory  Samples ....................................................... 51
9.1.11 Contraception and Pregnancy Avo idance Procedure ........................................... 53
[IP_ADDRESS] Male Subjects and Their Female Partners ................................................ 53
[IP_ADDRESS] Female Subjects and Their Male Partners ................................................ 53
[IP_ADDRESS] Definit ions and Procedures for Contraception and Pregnancy Avoidance .[ADDRESS_95641] ion and Analysis ................................................................... 57
[IP_ADDRESS] Bioanaly tical Methods ............................................................................. [ADDRESS_95642] ion and Analysis ................................................................... 57
[IP_ADDRESS] Bioanaly tical Methods ............................................................................. [ADDRESS_95643] Treatment Compliance .............................................................. 58
9.3 Schedule of Observat ions and Procedures ................................................................ 59
9.3.1 Screening ........................................................................................................... 59
9.3.2 Study  Entrance/Rando mizat ion.......................................................................... [ADDRESS_95644] Study  Care .................................................................................................. 59
9.4 Biological Sample Retent ion and Destruction .......................................................... 59
9.5 Blood Vol ume ......................................................................................................... 60
10.0 PRETREATMENT EVENTS AND AES ...................................................................... 62
10.1 Definit ions............................................................................................................... 62
10.1.1 PTEs .................................................................................................................. 62
10.1.2 AEs.................................................................................................................... 62
10.1.3 Addit ional Points to Consi der for PTEs and AEs ................................................ 62
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 8of 114
Protocol Incorporating Amendment No. 01 06October 2017
10.1.4 SAEs .................................................................................................................. 64
10.1.5 Intensit y of PTEs and AEs ................................................................................. 65
10.1.6 Causalit y of AEs................................................................................................ 65
10.1.7 Relationship to Study  Procedures ....................................................................... 65
10.1.8 Start Date ........................................................................................................... 66
10.1.9 Stop Date ........................................................................................................... 66
10.1.10 Frequency .................................................................................................... 66
10.1.11 Action Concerning Study  Drug .................................................................... 66
10.1.12 Outcom e....................................................................................................... 66
10.2 Procedures ............................................................................................................... 67
10.2.1 Colle ction and Reporti ng of AEs........................................................................ 67
[IP_ADDRESS] PTE and AE Collection Period .................................................................67
[IP_ADDRESS] PTE and AE Reporting ............................................................................ [ADDRESS_95645] igators, IRBs, and Regulatory  Authori ties.................. 69
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 70
12.0 DAT A HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645] ............................................................ 71
12.1 CRFs (El ectronic) .................................................................................................... [ADDRESS_95646] Retention ..................................................................................................... 71
13.0 STATISTICAL METHODS .......................................................................................... 73
13.1 Statistical and Analyt ical Plans ................................................................................ 73
13.1.1 Analysis Sets ...................................................................................................... 73
[IP_ADDRESS] Full Analysis Set ...................................................................................... 73
[IP_ADDRESS] Safety Analysis Set .................................................................................. 73
[IP_ADDRESS] PD Analysis Set ....................................................................................... 73
[IP_ADDRESS] Per-Protocol Set ....................................................................................... [ADDRESS_95647] ics........................... 73
13.1.3 Efficacy Analysis ............................................................................................... 74
[IP_ADDRESS] Primary Efficacy  Analysis ....................................................................... 74
[IP_ADDRESS] Secondary  Efficacy  Analysis ................................................................... 74
13.1.4 PK and PD Modeling Analysis ........................................................................... 74
13.1.5 PD Analysis ....................................................................................................... 75
13.1.6 Safety Analysis .................................................................................................. 75
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 9of 114
Protocol Incorporating Amendment No. 01 06October 2017
[IP_ADDRESS] Analysis of AEs ....................................................................................... 75
[IP_ADDRESS] Analysis of Other Safet y Assessments ..................................................... [ADDRESS_95648] OF IN -TEXT TABLES
Table 6.a Schemat ic of Study  Design ................................................................................ 30
Table 7.a Excluded/Allowed Medicat ions and Treatments ................................................. [ADDRESS_95649] OF I N-TEXT FIGURES
Figure 6.a Schemat ic of Study  Design ................................................................................ 31
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95650] igator Consent to Use of Personal Informat ion.......................................... 95
Appendix E Detailed Descript ion of Amendments to Text ..................................................... 96
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 11of 114
Protocol Incorporating Amendment No. 01 06October 2017
2.0 STUDY SUMMARY
Name [CONTACT_790]:
[COMPANY_005] Development Center Americas , Inc.Compound:
TAK -831
Title of Protocol: A Phase 2, Randomized, Double -Blind, 
Placebo -Controlled, Parallel -Arm Study t o Evaluate Efficacy, Tolerability, 
and Pharmacokinetics of Multiple Doses of Oral TAK -831 in Adult 
Subjects with Friedreich Ataxia IND No.:
132,633EudraCT No.:
Not Applicable
Study Number: TAK -831-1501 Phase: 2
Study Design:
TAK -831-1501 is a phase 2, randomized, double -blind, placebo -controlled, parallel -arm study designed to evaluate 
the efficacy, safety, pharmacodynamic (PD) effects, and pharmacokinetics (PK) of 2 dose levels of oral TAK -831 in 
adult subjects with Friedreich ataxia (FRDA). 
The study will include a Screening Period (Days -28 to -2), a Training Period (Day -1), Treatment (Days 1 to 84), a 
Phone Exit Interview (within [ADDRESS_95651] dose of study medication of the Double -Blind Treatment Period or 
within 7 days of notification of t ermination for the E arly Termination Visit), and a Safety  Follow -up P hone Call ([ADDRESS_95652] dose of study drug ).
Approximately [ADDRESS_95653] on efficacy assessment. On Day 1, subjects who continue to meet inclusion and 
none of the exclusion criteria will be randomized in a 2:1:[ADDRESS_95654] ratified by  [CONTACT_87784] (ambulatory vs nonambulatory).
Subjects will receive study drug or placebo dosing twice daily (BID) from Day [ADDRESS_95655] -perceived change due to treatment , 
and a S afety  Follow -up P hone Call will be conducted . 
Table 1. Schematic of Study Design
ScreeningEfficacy 
Assessment 
TrainingTreatment (TAK -831 high dose, 
TAK -831 low dose, or placebo)
Phone Exit 
InterviewSafety Follow -up 
Phone Call (a)Randomization, 
Baseline, and 
DosingEfficacy, PK, PD, and 
Safety Assessments
Days
-28 to -2Day -1 Day 1 Day 14 (±3 day s),
Day 49 (±3 day s), 
Day 84 (±2 day s)≤[ADDRESS_95656] dose
(a) The Follow -up phone call will occur [ADDRESS_95657] report 
concerning AEs. In these cases, subjects will be brought back into the clinic for re -evaluation at the investigator’s 
discretio n.
Primary Objective:
To evaluate the efficacy of TAK -831 versus placebo on upper extremity (arm and hands) motor function and 
manual dexterity, as measured by [CONTACT_941] [ADDRESS_95658] (9-HPT).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831- 1501 Page 12 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
Secondary Objectives:
!To evaluate the efficacy of TAK-831 versus placebo on Activities of Daily Living (ADL), as measured by [CONTACT_87785] (FARS), and those items that are related to upper limb 
function.
!To evaluate the efficacy of TAK-831 versus placebo on neurological function, as measured by [CONTACT_87786] (mFARS-neuro) Total Score. 
!To evaluate the efficacy of TAK-831 versus placebo on lower extremity motor function, as measured by [CONTACT_87787] 25-Foot Walk (T25FW).
!To evaluate the efficacy of TAK-831 versus placebo on limb ataxia, as measured by [CONTACT_87788] T25FW and 9-HPT.
!To evaluate the efficacy of TAK-[ADDRESS_95659] letter 
acuity (LCLA) testing with Sloan charts.
!To evaluate the efficacy of TAK-831 versus placebo on global improvement, as measured by [CONTACT_87789]-Improvement (CGI-I).
!To evaluate the efficacy of TAK-831 versus placebo on global improvement, as measured by [CONTACT_87790]-Improvement (PGI-I).
!To evaluate the efficacy of TAK-831 versus placebo on upper extremity functional improvement, as measured by 
[CONTACT_87791]-I.
!To evaluate the efficacy of TAK-831 versus placebo on upper extremity functional improvement, as measured by 
[CONTACT_87792]-I.
!To evaluate the efficacy of TAK-831 versus placebo on global severity, as measured by [CONTACT_87793]-Severity (CGI-S).
!To evaluate the efficacy of TAK-831 versus placebo on global severity, as measured by [CONTACT_87790]-Severity (PGI-S).
!To evaluate the efficacy of TAK-831 versus placebo on upper extremity functional severity, as measured by [CONTACT_87794]-S.
!To evaluate the efficacy of TAK-831 versus placebo on upper extremity functional severity, as measured by [CONTACT_87795]-S.
!To evaluate the safety and tolerability of TAK-831. 
Exploratory Objectives:
!To evaluate the efficacy of TAK-831 versus placebo on speech, as measured by [CONTACT_87796].
!To evaluate the efficacy of TAK-831 versus placebo on motor function such as gait, balance, and upper limb coordination, as measured by [CONTACT_87797].
!To evaluate the PK and PD (plasma D-serine and L-serine lev els and D-serine:Total serine ratios), and explore the 
relationships between TAK-831 exposures and D- a nd L-serine levels or selected measures of efficacy.
!To correlate plasma D-serine and L-serine levels, and D-serine:Total serine ratios with clinical parameters of 
disease status.
!To quantify subject-perceived meaningful change in upper limb motor function, as evaluated by [CONTACT_87798].
Property of [COMPANY_005]: For jectives:jective
uate the efate the
evaluate tvaluate
oordinatiordina
To evaTo er non-commercial use only and subject to the applicable Termsdified fied 
asured by [CONTACT_87799] b
compositempos
ed by [CONTACT_941] d by [CONTACT_87800], as ment, as m
provemenovemen
er extremr extre
on uppern uppe
placebo oacebo
versus plaersus p
K-831 ve831 v
y of TAKf TAK
safety andfety anms of Usemsms
rela
!r
yty
CCI
TAK-[ADDRESS_95660] Population: Male and female subjects aged 18 to 55 years, inclusive, with geneticall y-confirmed FRDA 
disease of stages 2 to 5, as determined by [CONTACT_87801], and able to complete the 9-HPT in 
≤150 seconds. 
Number of Subjects:
2:1:2 ratio for placebo, low, and high dose, 
respectively 
Estimated total: 65 subjects randomizedNumber of Sites: 
Approximately 6 or more specialized academic 
neurological clinical centers in the [LOCATION_002]
Dose Levels:
Placebo BID TAK-831 75 mg BIDTAK-831 300 mg BIDRoute of Administration:
Oral
Duration of Treatment:
12 weeksPeriod of Evaluation:
12 weeks of treatment + [ADDRESS_95661] 
administration of study drug
Main Criteria for Inclusion:
!The subject is an adult male or female aged 18 to 55 years, inclusive, with genetically-confirmed diagnosis (homozygous for guanine-adenine-adenine repeat expansions in the frataxin (FXN) gene in the affected range of 
FRDA or a compound heterozygous expansion with a point mutation or deletion), with an established disease 
stage of 2 to 5, inclusive, as determined by [CONTACT_87801], at Screening.
!The subject is able to complete the 9-HPT test in ≤150 seconds at Screening.
!Male subjects who are nonsterilized and sexu ally active with a female partner of childbearing potential must agree 
to use adequate contraception from signing of informed consent throughout the duration of the study and for 
[ADDRESS_95662] dose.
!Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and must agree 
to use adequate contraception from signing of informed consent throughout the duration of the study and for 
[ADDRESS_95663] dose.
!The subject is able to swallow study drug in tablet form. 
!If a subject requires a caregiver to accompany him/her during the study for clinic visits, a caregiver and backup 
caregivers should be available.
Main Criteria for Exclusion:
!The subject has a diagnosis of ataxic syndromes other than FRDA.
!The subject has, based on medical history and investigator clinical judgment, uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, endocrine disease (including 
uncontrolled diabetes), or other abnormality (other than the disease being studied), which may impact the ability of the subject to participate or potentially confound the efficacy and safety evaluation. The subject has medical history or conditions that, in the opi[INVESTIGATOR_871], may interfere with study conduct or clinical 
assessments.
!The subject has received treatment with other experimental therapi[INVESTIGATOR_48606] [ADDRESS_95664] dose of study drug. Property of [COMPANY_005]riteria foteria
The subjThe su
!TheTh
nda: For non-commercial use only an5 years, inyears, i
at expansixpan
n with a pwith
the Funche Fun
PT test inPT tes
d and sexand se
rom signinm sign
bearing paring 
aception fception
dose.se.
able to swble to 
ct requiresrequirand subject to the applicable T s of Usess
RDA RD
PT in i
d academacade
he United Uniteb
::he
Evaluatioaluati
ks of treaks of tre
inistrationnistratbje
vers shoulers shouan
da
ytyCCI
TAK -831
Study No. TAK -831-1501 Page 14of 114
Protocol Incorporating Amendment No. 01 06October 2017
The subject has a known hypersensitivity to any component of the formulation of TAK -831.
The subject has taken any excluded medication, or has had insufficient washout of medications as listed in the 
Excluded/Allowed Medications, Procedures, and Treatments table listed in Section 7.3 or is unable or unwilling 
to discontinue medications as required by [CONTACT_760].
The subject is considere d by [CONTACT_87802], others, or property 
or subjects who within the past year prior to Screening have attempted suicide or have positive answers on item 
4or 5 on the Columbia Suicide Severity Rating Sc ale ([C -SSRS], life -time version) at Screening or Day 1.
The subject has clinically significant cardiac abnormalities at Screening that, in the opi[INVESTIGATOR_871], 
would make the subject unsuitable for enrollment, including but not limited to hear t failure meeting criteria for 
class IV insufficiency by [CONTACT_87803] <40%. 
The subject has a QT interval with Fridericia correction method (QTcF) >450 ms (males) or>470 ms (females), 
confirmed with 1 repe at testing, at Screening or Day 1.
If female, the subject is of childbearing potential and lactating, pregnant (positive prerandomization serum 
pregnancy test), or plans to become pregnant before participating in the study, during the study, or within [ADDRESS_95665] dose of the study drug.
Main Criteria for Evaluation and Analyses:
Primary  Endpoint
The primary endpoint for this study is the change from Baseline to Week 12 in the inverse of the time to complete the 
9-HPT (9 -HPT-1) after treatment with TAK -831, compared with placebo . 
Secondary endpoints
The change from Baseline to Week s 2, 7, and 12on the ADL component of the FARS, after treatment with 
TAK -831, compared with placebo. 
The change from Baseline to Week s 2, 7, and 12 on the ADL component upper limb function items (ADL items 
3-5) of the FARS, after treatment with TAK - 831, compared with placebo. 
The change from Baseline to Weeks 2 and 7 on the 9 -HPT after treatment with TAK -831, compared with placebo.
The change from Baseline to Weeks 2 and 7 on the ADL individual items after treatment with TAK -831, 
compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on the mFARs -neuro total score after treatment with TAK -831, 
compared with placebo.
The change from Baseline to Weeks 2, 7, a nd 12 on the mFARS -neuro subscales and individual items after 
treatment with TAK -831, compared with placebo. 
The change from Baseline to Weeks 2, 7, and 12 on the T25FW after treatment with TAK -831, compared with 
placebo.
The change from Baseline to Weeks 2, 7, and 12 on the 9 -HPT and T25FW composite score after treatment with 
TAK -831, compared with placebo.
Percentage of subjects whose [ADDRESS_95666] 15% and at least 20% from Baseline.
The change from Baseline to Weeks 2, 7, and [ADDRESS_95667] score after treatment, compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on CGI -I (global change) after treatment with TAK -831, 
compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on PGI -I (global change) after treatment with TAK -831, 
compared with placebo. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 15of 114
Protocol Incorporating Amendment No. 01 06October 2017
The change from Baseline to Weeks 2, 7, and 12 on CGI -I (upper extremity functional change) after treatment 
with TAK -831, compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on PGI -I (upper extremity functional change) after treatment 
with TAK -831, compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on CGI -S (global severity ) after treatment with TAK -831, 
compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on PGI -S (global severity ) after treatment with TAK -831, 
compared with placebo. 
The change from Baseline to Weeks 2, 7, and 12 on CGI -S (upper extremity functional severity) af ter treatment 
with TAK -831, compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on PGI -S (upper extremity functional severity) after treatment 
with TAK -831, compared with placebo. 
Safety endpoints
Adverse events and clinical laboratory and electrocardiogram measures after treatment with TAK -831, compared 
with placebo.
Assessment of suicidal ideation and behavior as measured by [CONTACT_941] C -SSRS at Screening, Baseline, and all other 
timepoints.
Explo ratory  endpoints
The change from Baseline to Weeks 2, 7 and 12 on the digital speech assessment after treatment with TAK -831, 
compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on the digital motor sensors measurements such as gait, stability 
and upper limb coordination after treat ment with TAK -831, compared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on TAK -831 plasma D -serine and L -serine levels and 
D-serine:Total serine ratios after treatment with TAK -831, compared with placebo.
Percent of subjects reporting a meaningful change in upper limb function from Baseline to Week 12 after 
treatment with TAK -831, compared with placebo, as evaluated by [CONTACT_87798]. 
Correlation of change in 9 -HPT with that of patient reported improve ment of change in upper lim b function, such 
as ADL items 3 to 5 and PGI. 
TAK -831 plasma concentration.
Statistical Considerations:
The primary endpoint for this study is the change from Baseline to Week 12 in the inverse of the time to complete the 
9-HPT (9-HPT-1) after treatment with TAK -831, compared with placebo. The 2 TAK -831 doses will be compared 
with placebo, controlling multiplicity using Holm’s method. The dose with the smaller p -value will be tested at the 
1-sided 0.05 level, then the dose with the larger p - value will be tested at the 1-sided 0.10 level only if the smaller 
p-value is significant. This procedure will control the overall type I error rate at the 1 -sided 0.10 level.
Sample Size Justification:
Approximately 65 subjects will be rando mized in a 2:1:2 ratio to the high dose, low dose, or placebo, respectively. It is 
assumed that approximately 60 subjects (92%) will complete [ADDRESS_95668] size of 0.6 for each dose, this approach gives 77% power for at least 
1dose to be deemed superior to placebo and 54% power for both doses. The effect siz e was chosen based on expert 
advice that a treatment effect equivalent to preventing or reversing 2 years of decline due to Friedreich ataxia (FDRA )
would be clinically meaningful. The target effect size should be approximately 0.6 for each endpoint. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 16of 114
Protocol Incorporating Amendment No. 01 06October 2017
2.1 Protocol Amendment No. 01 Summary of Changes 
Rationale for Amendment No. 01
This document describes the changes in reference to the protocol incorporating Amendment 
No.01. The primary reasons for this amendment are to amend the dose, clarify/recategorize study 
objectives and endpoints, modify study procedures to reduce the number of visits and blood draws 
and update randomizat ion scheme, cl arify study  entrance cri teria and excluded medications, 
update the clinical data summary , and add a n internal Data Mo nitoring Co mmittee (DMC). 
Personnel changes, inconsistencies, and minor grammat ical, editorial, and formatting changes are 
included for clarificat ion purposes only .
For specific descript ion of text changes and where the changes are located, see Appendix E. 
Changes in Amendment No. 01
1.Revisio n of study procedures (reduce the number of visit s and blood draws, and update the 
rando mizat ion scheme) .
2.Revisio n of TAK -[ADDRESS_95669].
5.Revisio n and clarification o f study  entry
 criteria.
6.Clarificat ion of excluded medications and products.
7.Revisio n of stati stical analysis .
8.Inclusio n of the summary of clinical data fro m Studi es TAK -831- 1004 and TAK - 831-1005.
9.Engagement of a n internal DMC to revi ew unblinded safet y data. 
10.Personnel change
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95670] of clinical research 
as well as study  parti cipati on. The Si gnatory  Coordinat ing Investigator will be required to review 
and sign the clinical study  report and by [CONTACT_39771] .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95671] aspartate aminotransferase
AUC ∞ area under the concentration -time curve from time 0 to infinity
BID twice daily
BMI body mass index
CFR Code of Federal Regulations
CGI Clinical Global Impression Scale
CGI-I Clinical Global Impression -Improvement 
CGI-S Clinical Global Impression -Severity 
Cmax maximum observed concentration
CNS central nervous system
CSF cerebrospi[INVESTIGATOR_872]
C-SSRS Columbia -Suicide Severity Rating Scale
DAO D-amino acid oxidase
ECG electrocardiogram, electrocardiographic
eCRF electronic case report form 
EIIBs eosinophilic intranuclear inclusion bodies
FACOMS Friedreich Ataxia Clinical Outcome Measures Study
FARS Friedreich Ataxia Rating Scale
FAS full analy sis set
FDA Food and Drug Administration
FRDA Friedreich ataxia
FSH follicle -stimulating hormone
FXN frataxin gene
GAA guanine -adenine -adenine
GCP Good Clinical Practice
GGT gamma -glutamyl transferase
hCG human chorionic gonadotropin
HIV human immunodeficiency virus
HPLC high-performance liquid chromatography
HRQoL health -related quality of life
ICH The International Council for Harmonisation 
ID identification
IEC independent ethics committee
INR internatio nal no rmalized ratio
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-[ADDRESS_95672] multiple-rising dose
NMDA N-methyl- D-aspartate
PD pharmacodynamic(s)
PET positron emission tomography
PGI-I Patient Global Impression-Improvement
PGI-S Patient Global Impression-Severity
PGx pharmacogenomics
PTE pretreatment event
QTcF QT interval with Fridericia correction method 
SAE serious adverse event
SAP statistical analysis plan
SRD single-rising dose
S[LOCATION_003]R suspected unexp ected serious adverse reaction
T25FW Timed 25-Foot Walk
UGT uridine 5'-diphosphate glucuronosyltransferase
ULN upper limit of normal
3.4 Corporate Identification
TDC Europe [COMPANY_005] Development Centre Europe Ltd.
TDC Americas [COMPANY_005] Development Center Americas, Inc.
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable[COMPANY_005] TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Usecorrectionorrecti
lann
e
expected xpecte
Foot WaFoot W
e 5'5'--diphdip
pper limit per lim
dentificentifC
CI
TAK -831
Study No. TAK -831-1501 Page 20of 114
Protocol Incorporating Amendment No. 01 06October 2017
4.0 INTRODUCTION
4.1 Background
4.1.1 Study Drug
TAK -831 i s a highly selective and potent small mo lecule inhibitor of D -amino acid oxidase 
(DAO) being developed by  [CONTACT_11750]. DAO is the major enzym e responsible for the 
catabolism/degradation o f small neutral amino acids like D -serine and is highly expressed in the 
cerebellum [1]. Inhibit ing DAO leads to a measurable increase in D -serine levels in plasma, 
cerebrospi[INVESTIGATOR_872] (CSF), and cerebellum in rodents (Study  TAK -
831-[ZIP_CODE]) . D-serine is a 
potent N
-methy l-D-aspartate (NMDA) -type gl utamate receptor coagonist and an agonist for the 
2glutam ate receptor, whi ch has been implicated in synapt ic plast icity and l ong-term depressi on 
[
2,3]. As a DAO inhibitor that increases D -serine in the cerebellum, TAK -831 has the potential to 
increase NMDA -dependent glutamatergic signaling. The literature suggests that D -serine is a 
critical mediator of gl utam ate receptor –dependent funct ions of the cere bellum, which coordinates 
muscular activit y [2,3]. Therefore, inhibit ion of DAO and a subsequent increase in D -serine in the 
cerebellum may  lead to an improvement in cerebellar output.
4.1.2 Friedreich Ataxia
Ataxia manifests as impaired coordinat ion of  muscle m ovements. It i s a nonspecific clinical 
manifestation indicat ive of dysfunction in the parts of the central nervous system (CNS) that 
coordinate movement. Patients with ataxia have trouble regulat ing the force, range, direct ion, 
velocit y, and rhythm of muscle contractions, resulting in a characterist ic type o f irregular, 
uncoordinated movement that can manifest itself in many possible ways, such as asthenia, 
asynergy , delayed reacti on time, and dyschrono metria [
4]. Patients also display instabilit y of gait, 
difficult y with eye m ovements, dysarthria, dysphag ia, hypotonia, dysmetria, and 
dysdiadochokinesia (impaired abilit y to perform  rapid, alternating movements). These difficult ies 
can affect emplo yabilit y, lead to di sabili ty, increase caregiver burden, and significant ly reduce a 
person’s healt h
-related qual ity of life (HRQoL) [5]. 
There are numerous ty pes of  ataxias, m any genet ically mediated and others idiopathic. Friedreich 
ataxi a (FRDA) i s the m ost comm on of the hereditary  ataxi as and occurs in approximately 50% of 
overall cases of hered itary ataxia in Europe and North America (prevalence of 1:50,000 
Caucasians) [
6,7]. The number of individuals affected with FRDA at any given t ime in the United 
States i s approximately  5,000 [
8]. In people with FRDA, a guanine -adenine -adenine (GAA) 
trinucleoti de repeat expansio n mutation in intron 1 of the frataxin gene (FXN) results in drast ically 
reduced l evels of the frataxin protein [
9,10] , which in turn leads to mitochondrial dysfunct ion, 
neurodegenerat ion, cardio myopathy, diabetes mellitus, and skeletal deformit ies [7,11,12] . A small 
number of cases are caused by a co mpound heterozygous expans ion with a point m utation or 
deletion [
12]. This disorder has a sensory ataxia component secondary to involvement of the dorsal 
root ganglia and spi[INVESTIGATOR_87758], with loss of proprioceptive funct ion and sensory  
neuropathy , as well as gradual decreases in sensory  function that l ead to visual and he aring 
impairments [
13]. There i s also progressive destruction of the cerebe llar dentate nucleus and the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95673] [13]. FRDA is a debilitati ng, life -shortening, and degenerat ive multiple system 
disorder. Onset of symptoms can vary  from 5years old to adul thood, wi th the childhood onset 
tending to be associated with a more rapid progression. A progressive loss of coordinat ion and 
muscle strengt h leads to motor incapacitat ion and often the full -time use of a wheelchair. Most 
young people diagnosed with FRDA require mobility aids such as a cane, walker, or wheelchair by 
[CONTACT_87804]. As a rare disease with no currently approved tr eatments, FRDA 
represents an area of significant unmet medical need.
Various com pounds are under invest igation [14]. However, there is current ly no cure or approved 
effect ive treatment fo r FRDA [
15]. Thus, there is a great need to ident ify and develop effect ive 
therapi [INVESTIGATOR_87759].
4.1.3 Nonclinical Background
In nonclinica l studi es, TAK -831 increased D -serine l evels in rat cerebellum and plasma. In the 
YG8sR transgenic mouse model, a model relevant for FRDA, TAK
-831 at an oral daily dose of 
3mg/kg significant ly improved motor coordinat ion deficit s of the m utant mice in the beam -walk 
test. Five hours after administration of the first dose, TAK-831–treated m utant mice crossed the 
beam approximately  30% f aster than vehicle -treated animals, and TAK -831 treatm ent com pletely 
reversed the motor coordinat ion deficit in these mice b ack to B aseline observed in healt hy mice on 
Day 15. Therefore, TAK -831 ho lds the potential to treat patients with FRDA.
In vivo enzyme occupancy studies with a tracer molecule in mice demo nstrated that TAK -
831 
binds to DAO in the kidney, cerebellum, and br ain stem  in a dose -dependent manner. Increasing 
enzyme occupancy by [CONTACT_4129] -831 in the cerebellum correlated with plasma concentrations of drug, 
with maximal enzyme occupancy achieved at a dose of 10 mg/kg in mice.
Cerebellar enzyme act ivity was examined ex vi vo. TAK -831 potently  inhibi ted DAO activit y in 
mouse cerebellum in a dose -dependent manner with a 50% inhibitory  dose for DAO activit y at 
10mg/kg. Similarly, TAK -[ADDRESS_95674] observed at an oral dose of 10 mg/kg at [ADDRESS_95675] igator’s Brochure.
4.1.[ADDRESS_95676] been conducted in healt hy subjects: a first -in-human study  to 
determine the pharmacokinet ic (PK) profiles of TAK -831 oral  suspensi on after single -rising dose 
(SRD) and m ultiple-rising dose (MRD) administration, as well as the relat ive bioavailabilit y and 
effect of food on the PK of the T1 tablet formulat ion of TAK-831 (T AK-831- 1001); and a study to 
demonstrate DAO target engagement in the brain as measured by  [CONTACT_87805]  
(PET) (TAK -
831-1003). Plasma D -serine levels, TAK -[ADDRESS_95677], 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 22of 114
Protocol Incorporating Amendment No. 01 06October 2017
bioavailabilit y study with the T2 tablet formulat ion (TAK -831- 1004) has co mpleted active dosing, 
and a study  examining addit ional escalat ing mu
ltiple doses of TAK -831 higher than those 
achieved in the TAK -831-1001 study  was init iated and is ongoing (TAK - 831-1005).
After both single and mult iple dosing wit h TAK -831 (Study  TAK-
831-1001), increases in the area 
under the effect curve fro m time 0 to 24 hours of D -
serine were dose- dependent; changes in 
D-serine were noticeably higher after mult iple daily doses of TAK -831 400 mg than after mult iple 
daily  doses o f TAK -831 30, 100, and 200 mg. Single oral doses of TAK -831 temporally increased 
plasma concentrations of D -serine in the PET study  (TAK -831- 1003); the results are similar to 
those obtained fro m Study  TAK -
831-1001.
TAK -[ADDRESS_95678] commo n 
treatm ent-emergent advers e event (TEAE) potentially related to treatment. Headaches were mild 
to moderate in intensit y and generally  self-limit ing. The rate of postural dizziness in 
TAK -831- treated subjects did not markedly  differ from  the rate observed in placebo -treated 
subjects . There were no concerning trends in laboratory , electrocardi ogram  (ECG), or vi tal sign 
data.
TAK -
831-1004 was a phase 1, randomized, open -label, single -dose, 2 -period crossover study 
designed to characterize the pharmacokinet ics (PK) of a single dose of [ADDRESS_95679] of food on the bioavailabilit y of TAK-831 400 mg when administered as 4 100 mg 
oral tablets of  the T2 form ulation in 15 healt hy adult subjects. In the TAK -831- 1004 study , there 
was only a single adverse event ( AE)of mild upper respi[INVESTIGATOR_87760], judged to be 
unrelated to study  treatment. One subject met criteria for orthostatic hypotensio n at a single time 
point without an accompanying report of a dizziness AE. There were no concerning trends in 
laboratory , 
ECG, or vital sign data . TAK -831 given as T2 tablet co administered with the 
nutritional drink (Ensure Plus) increased mean C maxand AUC ∞values by 35% and 21%, 
respectively . Treatm ent wi th a single oral  dose of 400m g TAK -[ADDRESS_95680] blinded, sponsor unblinded, 
placebo -controlled clinical study  progressively assessing independent cohorts of hea lthy subjects 
to con tinue evaluat ion of the safet y, tolerabilit y, PK, and pharmacodynamics (PD) of escalat ing 
multiple doses of TAK -[ADDRESS_95681] to change upon finalizat ion following study  monitoring, source data 
verification, and discrepancy query management prior to database lock. At this t ime, 2cohorts 
with 8 subjects each ([ADDRESS_95682] acebo) have co mpleted treatment at dose levels of 600 
mg QD (T2 tablet formulation) or 800 mg QD (oral suspensio n) administered first as a single dose, 
and then administered for up to [ADDRESS_95683] ion for a 24 hour period 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95684] common treatment -emergent AEs; 
nausea in the absence of post -lumbar puncture syndrome was reported by  [CONTACT_87806]. All epi[INVESTIGATOR_87761] y and self -limit ing. Two subjects in each cohort 
met categori cal criteria f or orthostati c hypotensio n on at l east one assessment; none of these 
findings were associated with an AE of dizziness. There were no concerning trends in laboratory , 
ECG, or vital s ign data collected in these cohorts. 
Following once -daily  dosing, mean plasma exposures of TAK -831 were higher (C max: 1.3-fold and 
AUC: 1.8 -fold) when dosed as an oral suspensio n than as T2 tablets. Geometric mean C maxvalues 
were 1466 and 1976 ng/mL with 600 m g QD (T2 tablet form ulation) and 800 mg QD (oral 
suspension), respect ively. Mean steady -state exposures (AUC t) over the 24 -hour dosing interval 
were on average 4993 and 8853 ng.hr/mL for the respect ive [ADDRESS_95685] curve fro m time 0 to 24 hours of CSF D- serine for both the 
600mg T2 and 800 mg oral suspensio n treatment groups when compared to placebo; changes in 
CSF D -serine were noticeably higher after mult iple doses of TAK -[ADDRESS_95686] the efficacy  and safet y of TAK -831 in subjects with
FRDA. The literature suggests that D-serine is a critical mediator of glutamate receptor –dependent 
funct ions of the cerebellum and was shown to reduce ataxi ain animal model o f spi[INVESTIGATOR_87762] a [
3]. As a DAO in hibitor that increases D -serine in the cerebellum, TAK -831 has the 
potenti al to increase NMDA -dependent glutamatergic signaling. One disease state that could be 
treated through this mechanism is FRDA. TAK -831 showed efficacy  in a m ouse m odel of FRDA 
with single doses and dosed daily  for 15 days at 3 mg/kg. 
There i s currently no cure or approved effect ive treatment for FRDA [14]. Thus, there is a great 
need to ident ify and develop effective therapie s for pati entpopulat ions wit h ataxia. The current 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95687] to explore the potential benefit s of TAK -831 
in this populat ion. 
4.3 Benefit/Risk Profile 
The proposed phase [ADDRESS_95688]/MRD studies 
(TAK -831- 1001 and TAK - 831-1005), brain target occ upancy data from the PET study  
(TAK -
831-1003), CSF D -serine data from the TAK - 831-[ADDRESS_95689] not resul ted in a safet y signal that 
woul d prevent addi tional studi es in subjects with FRDA. 
Potenti al risks, and ri sk mi tigation measures to be implemented in studies with TAK -831, are 
described below. These measures are based on what is known about the mechanism o f action of 
TAK -831, nonclinical data, the phase 1 studies conducted to date, and general considerat ions in 
the development of new chemical ent it
ies. These procedures may be modified during the study  if 
necessary  based on eva luation of any  addi tional clinical or nonclinical safet y data.
Acute hypersensit ivity/anaphylact ic reactions to new chemical entit ies are al ways a possible 
risk in any clinical study . Appropri ate procedures should be used to manage such possible 
risks. 
Subjects with a risk of suicide according to the investigator’s clinical judgment (eg, per the 
Columbia -Suicide Severit y Rating Scale [C -SSRS]) [16,17] or who have made a suicide 
attem pt in the previous [ADDRESS_95690] ituted, if warranted.
Emesis and diarrhea were reported in laboratory  animals exposed to TAK -831. If a subject 
develop s emesis or di arrhea, the invest igator should assess the clinical status. For mild emesis 
or diarrhea that i s self -
limited, the subject should be encouraged to increase fluid intake. 
Hydration status should be assessed wit h physical examinat ion and vital s igns, including 
orthostati c pulse and blood pressure measurements. For more severe emesis or diarrhea, where 
the subject has had more than 3 epi[INVESTIGATOR_87763] 
(ie, lightheadedness, vert igo, syncope, and/or orthostat ic changes in blood pressure or pulse 
are present), measurement of serum electrolytes, blood urea nitrogen, and creatinine, as well as 
the consideration o f more aggressive hydration, including the administration o f an appropriate 
parenteral  solution, shoul d be undertaken.
Eosinophilic intranuclear inclusio n bodies (EIIBs) were observed in the proximal tubule 
epi[INVESTIGATOR_87764] ≥10mg/kg/day in rats. The EIIBs were not accompanied 
by [CONTACT_87807], inflammat ion, or impaired renal funct ion and were not considered 
adverse. Similar findings have been reported in the literature and are considered to be 
species -specific to the rat [18]. Creatinine will be measured in the clinical st udies.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 25of 114
Protocol Incorporating Amendment No. 01 06October 2017
Postural hypotensio n and dizziness were observed in prior studies in healt hy subjects. 
However, the incidence of dizziness in subjects treated with TAK -[ADDRESS_95691] ion, and thus are suscept ible to 
fall, subjects should be instructed to take appropriate precautionary measures to prevent falling 
while under treatment with TAK -831. Addit ionally , subjects wi th current hi story  of 
symptom atic orthostatic hypotensio nwill be excluded fro m the study .
Study  procedure –specific risks include issues relat ing to the requirement for fasting (wh ich 
may lead to AEs of lightheadedness or stomach cramps) as well as blood collect ion for safet y 
assessment/PK monitoring (venipunctu re may cause bruising), and the placement.
The invest igator has discret ion to use his/her clinical judgment as to whether to allow a subject to 
proceed in the study  or whether to unblind the subject in order to determine his/her treatment 
allocat ion. These cases woul d norm ally be di scussed wi th the sponsor beforehand, but that is not 
an abso lute requirement in case of medical emergency, and the clinical needs of the individual 
subject will always take precedence.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95692] ive o f the study is to evaluate the efficacy o f TAK-831 versus placebo on upper 
extremit y (arms and hands) m otor f uncti on and manual dexterit y, as m easured by [CONTACT_941] 9-hole peg 
test ( 9
-HPT).
5.1.2 Secondary Objectives
Toevaluate the efficacy o f TAK -831 versus placebo on Activities o f Daily Living (ADL), as 
measured by [CONTACT_87808] (FARS), and those 
items that are related to upper limb funct ion.
To evaluate the efficacy o f TAK -[ADDRESS_95693] ion, as measured by 
[CONTACT_87809] F ARS neuro logical examinat ion (mFARS -neuro) total s core. 
To evaluate the efficacy  of TAK -831 versus placebo on lower extremit y motor function, as 
measured by [CONTACT_87810] 25 -Foot Walk (T2 5FW).
To evaluate the efficacy  of TAK -831 versus placebo on limb ataxia, as measured by  [CONTACT_87811] T25FW and 9
-HPT.
To evaluate the efficacy  of TAK -[ADDRESS_95694] l etter acui ty (LCLA) testing with Sloan charts.
To evaluate the efficacy  of TAK -831 versus placebo on global improvement, as measured by 
[CONTACT_87812]-Improvement (CGI -I).
To evaluate the efficacy  of TAK -831 versus placebo on global improvement, as measured by
[CONTACT_87813] n-Improvement (PGI -I).
To evaluate the efficacy  of TAK -[ADDRESS_95695] ional 
improvement, as measured by  [CONTACT_87791] -I.
To evaluate the efficacy  of TAK -[ADDRESS_95696] ional 
improvement , as m easured by  [CONTACT_87792] -I.
To evaluate the efficacy  of TAK -831 versus placebo on global severit y, as measured by  [CONTACT_87814] -Severi ty (CGI -S).
To evaluate the efficacy  of TAK -831 versus placebo on global severit y, as measured by [CONTACT_87815]-Severi ty (PGI -S).
To evaluate the efficacy o f TAK-831 versus placebo on upper extremit y functional severit y, as 
measured by [CONTACT_87791] -S.
To evaluate the efficacy o f TAK-831 versus placebo on upper extremit y functional severit y, as 
meas ured by [CONTACT_87792] -S.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831- 1501 Page 27 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
!To evaluate the safety and tolerability of TAK-831.
5.1.3 Exploratory Objectives
!To evaluate the efficacy of TAK-831 versus placebo on speech, as measured by [CONTACT_87816].
!To evaluate the efficacy of TAK-831 versus placebo on motor function such as gait, balance, 
and upper limb coordination, as measured by [CONTACT_87797].
!To evaluate the PK and PD (plasma D-serine and L-serine levels and D-serine:Total serine 
ratios), and explore the relationships between  TAK-831 exposures and D- and L-serine levels 
or selected measur es of efficacy.
!To correlate plasma D-serine and L-serine levels , and D-serine:Total serine ratios with clinical 
parameters of disease status.
!To quantify subject-perceived meaningful change in upper limb function, as evaluated by [CONTACT_87817]. 
5.2 Endpoints
5.2.1 Primary Endpoint
The primary endpoint for this study is the change  from Baseline to Week 12 in the inverse of the 
time to complete the 9-HPT (9-HPT-1) after treatment with TAK-831, compared with placebo.
5.2.2 Secondary Endpoints
!The change from Baseline to Weeks 2, 7, and 12 on the ADL component of the FARS, after 
treatment with TAK-831, compared with placebo. 
!The change from Baseline to Weeks 2, 7, and 12 on the ADL component upper limb function 
items (ADL items 3 to 5) of the FARS, af ter treatment with TAK-831, compared with placebo. 
!The change from Baseline to Weeks 2 and 7 on the 9-HPT-1after treatment with TAK-831, 
compared with placebo.
!The change from Baseline to Weeks 2, 7, and 12 on the ADL individual items after treatment 
with TAK-831, compared with placebo. Property of [COMPANY_005]: For non-commeointint
nt for thit for 
the 9-e 9-HPH
condaryndar
change hange
eatmeatm enten
The cThe
it
!subject to the applicable Terms of Usegaiait, balt, baiiii
erine:Toine:T
D-and and
Total serotal 
per limb r limb
CCI
TAK -831
Study No. TAK -831-1501 Page 28of 114
Protocol Incorporating Amendment No. 01 06October 2017
The change from Baseline to Weeks 2, 7, and 12 on the mFARs -neuro total  score after 
treatm ent wi th TAK -831, com pared wi th placebo.
The change from Baseline to Weeks 2, 7, and 12 on the mFARS -neuro subscales and 
individual items after treatment with TAK -831, compared with placebo. 
The change fro m Ba seline to Weeks 2, 7, and 12 on the T25FW after treatment with TAK -831, 
compared wi th placebo.
The change from Baseline to Weeks 2, 7, and 12 on the 9-HPT and T25FW composite score 
after treatm ent wi th TAK -831, com pared wi th placebo.
Percentage of subjects whose [ADDRESS_95697] 15% and at l east 
20% from B aseline.
The change fro m Baseline to Weeks 2, 7, and [ADDRESS_95698] score after treatm ent, compared 
with placebo.
The change from Baseline to Weeks 2, 7, and 12 on CGI -I (global change) after treatment wit h 
TAK -831, com pared wi th placebo.
The change from Baseline to Weeks 2, 7, and 12 on PGI -I (global change) after treatment with 
TAK -831, com pared wi th placebo. 
The change fro m Ba seline to Weeks 2, 7, and 12 on CGI -I (upper extremit y functional change) 
after treatm ent wi th TAK -831, com pared wi th placebo.
The change from Baseline to Weeks 2, 7, and 12 on PGI -I (upper extremit y functional change) 
after treatm ent wi th TAK -831, com pared with placebo.
The change from Baseline to Weeks 2, 7, and 12 on CGI -S (global severit y) after treatment 
with TAK -831, com pared wi th placebo.
The change from Baseline to Weeks 2, 7, and 12 on PGI- S (global severit y) after treatm ent 
with TAK -831, com pared wi th placebo. 
The change from Baseline to Weeks 2, 7, and 12 on CGI -S (upper extremit y functional 
severit y) after treatm ent wi th TAK -831, com pared wi th placebo. 
The change from Baseline to Weeks 2, 7, and 12 on PGI- S (upper extremit y funct ional 
severit y) after treatment with TAK -831, com pared wi th placebo.
5.2.3 Safety Endpoints
AEs, clinical laboratory  assessments, ECG m easures, changes in physical examinat ions and 
vital signs after treatm ent wi th TAK -831, com pared wi th placebo.
Assessment of suicidal ideat ion and behavior as measured by [CONTACT_941] C -SSRS at Screening, 
Baseline, and all other timepo ints after treatm ent wi th TAK -831, com pared wi th placebo .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 29of 114
Protocol Incorporating Amendment No. 01 06October 2017
5.2.4 Exploratory Endpoints
The change from Baseline to Weeks 2, 7, and 12 on the digital speech assessment after 
treatm ent with TAK -831, com pared wi th placebo.
The change from Baseline to Weeks 2, 7, and 12 on the digital motor sensors measurements 
such as gait, stabilit y and upper limb coordinat ion after treatment with TAK -831, com pared 
with placebo.
The change from Baselin e to Weeks 2, 7, and [ADDRESS_95699] asma D -serine and L -serine 
levels and D -serine:Total serine ratios after treatment with TAK -831, com pared wi th placebo.
Percent of subjects reporting a meaningful change in upper limb function fro m Baseline to 
Week 12 a fter treatment with TAK -831, com pared wi th placebo, as evaluated by [CONTACT_87818].
Correl ation of change in 9- HPT wi th that of pati ent reported improvement of change in upper 
limb funct ion, such as ADL items 3 to 5 and PGI.
TAK -831 pl asma concentrati on.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95700] acebo -controlled, parallel -arm study  
designed to evaluate the efficacy, safety , PD effects, and PK of 2 dose levels of oral TAK -831 in 
adult sub jects with FRDA. 
The study  will include a Screening Period (Days -28 to -2), a Training Period (Day -1), Treatment  
(Day s 1 to 84), a Phone Exit Intervi ew (within [ADDRESS_95701] dose of study medicat ion of the 
Doubl e
-Blind Treatm ent Peri od or wi thin 7 days of notificat ion of terminat ion for the E arly 
Terminat ion Visit) , and a Safety Follow-up P hone Call ([ADDRESS_95702] dose of study drug) .
Approximately  65 subjects who m eet the study  criteria during Screening will be invited to attend 
training to minimize practice effects on performance- based efficacy assessments on Day  -1. On 
Day 1, subjects who continue to meet inclusio n and none of the exclusion criteria will be 
rando mized in a 2:1:2 ratio to TAK -831 high dose, TAK -831 l ow dose, or p lacebo, respectively. 
(If the rate of early wit hdrawal is substant ially greater than predicted, then an increase to the 
number of rando mized subjects may be considered.) Randomizat ion will be stratified by  
[CONTACT_87819] (ambulatory  vs. nonambulatory ).
The study  will be conducted in approximately 6 or more specialized academic neurological 
clinical centers in the [LOCATION_002] with expertise in, and access to, patients with FRDA.
Subjects will receive twice daily (BID) study drug dosing or placebo from D ay [ADDRESS_95703] ions, and laboratory  tests will  be conducted at specific time points per 
the schedule o f study  procedures ( Appendix A). A semistructured Exit Interview will be 
conducted by  [CONTACT_87820] -depth, qualitative evaluat ion of the subject experience and 
subject -perceived change due to treatment , and a S afety Follow-
up Phone Call will be conducted
(Table 6.a). 
Table 6.a Schematic of Study Design
ScreeningEfficacy 
Assessment 
TrainingTreatment (TAK -831 high dose, 
TAK -831 low dose, or placebo)
Phone Exit 
InterviewSafety Follow -up 
Phone Call (a)Randomization, 
Baseline, and 
DosingEfficacy, PK, PD, and 
Safety Assessments
Days
-28 to -2Day -1 Day 1 Day 14 (±3 day s), 
Day 49 (±3 day s), 
Day 84 (±2 day s)≤[ADDRESS_95704] dose
(a) The Follow -up Phone Call will occur [ADDRESS_95705] 
report concerning AEs. In these cases, subjects will be brought back into the clinic for re -evaluation at the 
investigator’s discretion .
A schemat ic of the study  design is included as Figure 6.a. A schedule o f assessments is listed in 
Appendix A.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 31of 114
Protocol Incorporating Amendment No. 01 06October 2017
Figure 6.a Schematic of Study Design
6.2 Justification for Study Design, Dose, and Endpoints
TAK -831 i s a selective inhibitor of DAO. Inhibit ion of DAO leads to higher D -serine levels in the 
plasma, CSF, and cerebellum of animal models. D -serine enhances glutamate receptor –med iated 
mechanisms tha t may be impaired or contribute to cerebellar dysfunct ion symptoms, such as 
ataxi a. Increasing D -serine levels by [CONTACT_87821]. Accordingly , the 
focus of this study  is to target and mit igate symptoms of cerebellar dysfunct ion in subjects with 
FRDA.
6.2.[ADDRESS_95706] populat ion (rather than 
limit ing the populat ion to ambulatory or nonambulatory, for example) will help ident ify subgroups Days -1, 1
(Visits 2, 3)Day 84 
(Visit 6)ScreeningRandomization & 
First Dose (Day 1)Screening Double -blind 
12weeks
FRDA  SubjectsTAK-831 High Dose BID
Placebo
Day -28 to -2 
(Visit 1)Last Diose 
VisitTAK-831 Low Dose BID
Day 14
(Visit 4)Day 49
(Visit 5)Safety
Follow -up
phone call
(7-[ADDRESS_95707] dose)Exit 
Interview  
(<[ADDRESS_95708] 
dose)
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95709] ional Ataxia Staging (total score range from 0 to 6). Stage [ADDRESS_95710] 
symptom atically wit h a rel atively  rapid onset of acti on (based on i ts mechanism of act ion and the 
nonclinical data), a duration of [ADDRESS_95711] of the drug. Twelve weeks is 
the maximum treatment duration supported by  [CONTACT_87822] -831 nonclinical 
toxicology data.
The sample size o f 65subjects being rando mized in a 2:1:[ADDRESS_95712] acebo, respectively, was based on the fo llowing assumpti
ons. It was assum ed that 
approximately  60 subjects (9 3%) will co mplete [ADDRESS_95713] size of 0.6 for each dose, this approach gives 77% power for at least  
1dose to be deemed superior to placebo and 54% power for both doses. The effect size was chosen 
based on expert advice that a treatment effect equivalent to prevent ing or reversing 2 years of 
decline due to FRDA would be clinically meaningful. Using published data [19], the target effect 
size shoul d be approximately 0.6 for each endpo int.
6.2.2 Justification of Dose
The doses of TAK -831 (300 mgand 75 m g BID) sel ected for the current study  are based on PK 
data from  the SRD/MRD study  (TAK -831- 1001) and brain target occupancy data from the PET 
study  (TAK -
831-1003), PK and food effect study  (TAK - 831-1004), CSF D -serine study 
(TAK -
831-1005), and saf ety data fro m all clinical studies after oral administration of TAK -831 in 
healt hy subjects. Preliminary  PK/PD m odeling analyses showed that the high dose regimen 
resul ted in steady -state exposures associated with peak target occupancy o f >90%. The lower d ose 
is to provide at least [ADDRESS_95714] ing that 
600 m g QD produced levels o f D-serine approaching maximal DAO inhibit ion in the brain. These 
2 doses (300 and 75 mg BID) may allow characterization of an exposure -response relat ionship 
with PD or efficacy  measures in adult su bjects with FRDA. Subjec ts will  be instructed to take 
3tablets by  [CONTACT_1966] 2times a day  in the fasted condit ion (at least 1 h ourbefore or after a meal) or 
with a light m eal (less than 600 calories total with <30% from fat) . This will  keep the TAK -[ADDRESS_95715] been shown to be well tolerated in healthy subjects . 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 33of 114
Protocol Incorporating Amendment No. 01 06October 2017
6.2.3 Justification of Measurements
[IP_ADDRESS] Primary Outcome Measure: 9 -HPT
The 9 -HPT is a quant itative performance -based measure of t imed upper extremit y (arm and hand) 
funct ion and manual dex terity.The 9 -HPT was developed in the 1970s as a performance -based 
measure of upper limb dexterit y [20]. Thi s measure has been used extensively  in stroke and 
Parkinson’s disease patients and is the gold standard test recommended by [CONTACT_87823] [
21]. The 9 -HPT 
has been used more recent ly in FRDA [19,22] and is recommended as the best performance -based 
measure of upper limb function for inclusio n in clinical studies of FRDA [
23].
Parti cipants pi[INVESTIGATOR_87765] 1 at a time (9 in total), using [ADDRESS_95716] with score interpretation [24-26] . This 
measure correlates with neuro logical disabilit y and disease duration as well as other 
perform ance-based measures in FRDA [
27]. Addi tional analysis o f natural  history  data based on 
the Friedreich Ataxia Clinical Outcome Measures Study (FACOMS) show a correlat ion of 9-HPT 
with ADL total  scores and subscores that reflect funct ions such as cutting food and handling 
utensils, dressing, and hygiene (personal co mmunications with Jennifer Farmer fro m Friedreich 
Ataxia Research Alliance and [CONTACT_87874]).
The [ADDRESS_95717] study  popul ation, and greater precisio n and accuracy  in outcom emeasurement over other 
measures including the T25FW, visual acuit y tests, mFARS, and ADL as indicated by  [CONTACT_87824] [
19], and fro m author personal co mmu nicati on. Anchor -and distribution -based methods in 
accordance with Food and Drug Administration (FDA) guidance [28] will be used to derive a 
responder definit ion for the 9 -HPT in the study  popul ation (see Section [IP_ADDRESS] )
.
[IP_ADDRESS] Secondary Outcome Measure: 
ADL
FARS ADL scale has a total score range of 0 to 36 (higher scores represent greater 
severit y/dependency). Each ADL subscale is scored from 0 (normal) to 4 (se vere 
disabili ty/inabili ty to carry  out activit y independently ). The [ADDRESS_95718] ion [29,30] .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 34of 114
Protocol Incorporating Amendment No. 01 06October 2017
mFARS -neuro
The FARS neurological examinat ion is based on neural substrates affected in FRDA includi ng 
bulbar, upper limb, lower limb, peripheral nerve, and upright stabilit y/gait functi ons (m aximum  
scores of 11, 36, 16, 26, and 36, respectively; maximum deficit=125) [29,31] . A funct ional staging 
was incorporated with a total score ranging from 0 to 6 (higher scores represent greater disabilit y). 
The mFARS -neuro is the modified versio n of the FARS neurological examinat ion that excludes 
the peripheral nerve component and bulba r assessment item [ADDRESS_95719] accurate measure of ambulation in FRDA [27,32] .The 
subject is directed to one end of a clearly marked [ADDRESS_95720] ive devices whe n 
doing this task.
The T25FW is a useful measure of lower limb function in ambulatory  FRDA pat ients and 
correl ates with disease status and duration as well as other performance -based measures in FRDA 
(including the 9- HPT) [27].
T25FW and 9 -HPT Composite Measure
The T25FW and 9-HPT will be evaluated togethe r as a perform ance-based composite measure of 
limb ataxia which has been shown to be a reliable assessment of function in FRDA [30]. The 
composite measure is created us ing the basic methods used in the MSFC [
33]. In brief, raw scores 
from each test are tabulated and converted to test -specific Z scores by [CONTACT_87825] n 
from the raw score, and then dividing by [CONTACT_87826] a Z score for the test. The inverse 
is taken for the 9
-HPT (9 -HPT-1). The composite Z scores will be created by [CONTACT_18647] Z -score 
for T25FW fro m the Z-score for 9 -HPT-1.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95721] ion, a highly prevalent manifes tation, in FRDA [34]. Testi ng will be performed 
binocularly  using Low -Contrast Sloan Letter Charts at different contrast levels. 
Clinical Global Impression (CGI -I, CGI -
S)
The Clinical Glo bal Im pressi on Scal e (CGI) provides an overall clinician -determined summary 
measure that takes into accoun t all available informat ion, including knowledge of the subject’s 
history ,psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the 
subject’s abilit y to functi on.
The CGI comprises 2 companio n 1-item measures evaluat ing the fo llowing: (a) CGI -S, severit y of 
psychopathol ogy from 1 to 7 and (b) CGI -I, improvement fro m the init iation o f treatm ent on a 
similar [ADDRESS_95722] ion.
Patient Global Impression (PGI -I, PGI -S)
The PGI rating scales capture global efficacy as perceived by [CONTACT_87827] “anchors” to 
determine clinically -relevant effects.
The PGI -S requires the subject to rate his/her disease severit y at the time of assessment on a 
5-point scale ranging fro m norm al to extremely  severe.
The PGI -I measures improvemen t due to treatm ent rel ative to B aseline on a 7 -point scale ranging 
from 1 (very  much improved) to 7 (very  much worse). 
The PGI -S and the PGI -I will be administered similarly to the CGI -S and CGI -
I.
[IP_ADDRESS] Exploratory Outcome Measures
Digital Quantification of Gait (for Ambulatory Patients Only), Upper Body Stability, and Upper 
Limb Movement
The use o f digital devices, such as the Lab Mobilit y Test, provides means o f object ive measures o f 
subject’s gait and stabilit y to expl ore the effect of TAK -[ADDRESS_95723] ively using acoustic 
analysis so ftware. This assessmen t is of an exploratory  nature and will be used to evaluate the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95724] of TAK -831 on voi ce characteri stics in ataxia [35]. Please refer to the Redenlab study  
manual for additional deta ils. 
Subject Exit Interview
A semistructured, qualitat ive subject Exit Interview is planned. The key object ives of the Exit 
Interview are as fo llows:
To understand the subject experience with FRDA (including symptoms and day -to-day 
impacts), previous man agement of symptoms, and treatment expectations.
To understand the most relevant and important outcomes that subjects desire so that 
meaningful treatment fro m the subject perspective can be better understood.
To evaluate the subject -perceived meaningfulnes s of change in upper limb funct ion due to 
TAK -831 (given the planned primary  endpoint).
To determine the overall percept ion of treatm ent wit h TAK -831.
The interviews will be conducted over the phone within [ADDRESS_95725] consent.
D-Serine Levels
Plasma D -serine levels could be used as a bio marker for peripheral inhibit ion of DAO enzyme. PD 
param eters will  be determined from the concentratio n-time profiles for all evaluable subjects. 
Actual  sampling times, rather than scheduled sampling times, will be used in all computations 
involving sampling t imes. 
6.3 Premature Termination or Suspension of Study or Study Site
6.3.1 Criteria for Premature Termination or Suspension of the Study
The study  will be co mpleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early  terminat ion of the study .
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study drug that 
indicates a change in the known risk/benefit profile for the TAK -831, such that the risk is no 
longer acceptable for subjects participat ing in the study . 
Significant vio lation of Good Clinical Practice (GCP) that compromises the abilit y to achi eve 
the primary  study  objectives or compromises subject safet y. 
Subjects experience any of the [COMPANY_005] Medically  Significant List events.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 37of 114
Protocol Incorporating Amendment No. 01 06October 2017
Abnorm al liver funct ion:
–Two or more subjects experience alanine aminotransferase (ALT) and/or aspartate 
aminotransfer ase (AST) elevat ions >5× the upper limit of normal (ULN) in the absence of 
a concomitant bilirubin increase.*
–One or more subjects experience ALT and/or AST elevations >3×ULN in the presence o f a 
total bilirubin increase >2×ULN or an international normaliz ed rati o (INR) >1.5 wi thout 
findings of cho lestasis or other alternate etiology to explain the elevat ions (ie, “Hy’s Law 
cases”).
–Two or more subjects experience ALT and/or AST elevat ions >3×ULN with the 
appearance of fat igue, nausea, vo miting, right upper quadrant pain or tenderness, fever, 
rash, and/or eosinophilia (>5%).
*Note that the study  may be terminated early  prior to f ull attainment of these cri teria (eg, if just [ADDRESS_95726] experiences 1 of these events) if warranted by [CONTACT_45308] y data from  the other s ubjects dosed in 
the study  to date.
6.3.2 Criteria for Premature Termination or Suspension of Study Sites
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study , or as otherwise permitted by  [CONTACT_39778].
6.3.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)
In the event that th e sponsor, an inst itutional review board (IRB), or regulatory  authori ty elects to 
terminate or suspend the study  or the parti cipat ion of a study  site, a study -specific procedure for 
early terminat ion or suspensio n will be provided by [CONTACT_456]; the proce dure will be fo llowed by 
[CONTACT_57791] n or study  suspensi on.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 38of 114
Protocol Incorporating Amendment No. 01 06October 2017
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results, need to be confirmed prior to randomizat ion.
7.[ADDRESS_95727] eligibilit y is determined according to the following criteria prior to entry  into the study : 
1.In the opi[INVESTIGATOR_3078] n of the invest igator, the subject is capable of understanding the informed consent, 
and capable of understanding and complying wit h protocol  requi rements .
2.The subject signs and dates a written, informed consent. 
3.The subject is an adult male or female aged [ADDRESS_95728] has a genet ically -confirmed diagnosis (ho mozygous for GAA re peat expansio ns in 
the FXN in the affected range of FRDA or a compound heterozy gous expansio n with a point 
mutati on or deletion), with an established disease stage of [ADDRESS_95729] in ≤[ADDRESS_95730] weighs ≥43 kg and has a body  mass index (BMI) between 16.0 and 40.0 kg/m2, 
inclusive at Screening.
7.A male subject who is nonsterilized* and sexually active wit h a female p artner of childbearing 
potenti al* agrees to use barrier method of contraception (eg, condom with spermicide cream or 
jelly)* from signing of informed consent throughout the duration of the study  and f or [ADDRESS_95731] ive/effective method of contraception.*
8.A female subject is of nonchildbearing potential or, a female subject of childbearing potential* 
who is sexually act ive with a nonsterilized* male partner agrees to use 2 highly 
effective/effective methods of contraception* from signing of informed consent throughout the 
durati on of  the study  and f or [ADDRESS_95732] dose.
*Definit ions and highly effect ive methods of contraception are defined in Section 9.1.[ADDRESS_95733] requires a caregiver to accompany him/her during the study for clinic visit s, a 
caregiver and backup caregivers should be available.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95734] who meets any  of the fo llowing cri teria will not qualify  for entry  into the study :
1.The subject has received a diagnosis of ataxic syndromes other than FRDA .
2.The subject has, based on medical history  and j udgment of the investigator, uncontrolled, 
clinically significant neurologic, cardiovascular, pulmo nary, hepat ic, renal, metabo lic, 
gastrointestinal, or endocrine disease (including uncontrolled diabetes) or other abnormalit y 
(other than the disease being studied), which may impact the abilit y of the subject to participate 
or potentially confound the efficacy and safet y evaluat ion. The subject has medical history  or 
condi tions that, in the opi[INVESTIGATOR_1649] o f the inve stigator, may interfere with study  conduct or clinical 
assessments.
3.The subject has received treatment with other experimental therapi[INVESTIGATOR_48606] [ADDRESS_95735] of this study  
(eg,spouse, parent, child, sibling) or may consent under duress.
5.The subject has a history  of cancer, except squam ous cell carcino ma or basal cell carcino ma 
that have been treated or excised, or in situ cervical cancer that has been in remissio n for ≥[ADDRESS_95736] a history of having been infected w ith human immunodeficiency 
virus (HIV), hepatit is B virus, or hepat itis C virus.
7.Urine drug screen positive for drugs of abuse at S creening or, except for a prescribed d rug 
allowed by [CONTACT_87828] S creening. Cannabino id use is not permitted either recre ationally or 
medically . 
8.The subject has a known hypersensit ivity to any  component of the formulat ion of TAK -831.
9.The subject has a history  of drug abuse (defined as any  illici t drug use) or a hi story  of alcohol  
abuse within [ADDRESS_95737] has taken any excluded medication, or has had insufficient washout of medicat ions 
as listed in the Excluded/Allo wed Medicat ions, Procedures, and Treatments table listed in 
Secti on7.3or is unable or unwilling to discont inue medicat ions as required by [CONTACT_760].
11.The subject is considered by [CONTACT_87829] o f suicide or injury to self, 
others, or property  or subjects who within th e past year prior to Screening have attempted 
suicide or have posit ive answers on item [ADDRESS_95738] unsuitable for enro llment, including but not limited to heart 
failure m eeting criteria for class IV insufficiency by [CONTACT_87830] <40%.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95739] has a QT interval with Frider icia correction method (QTcF) >450 msec (males) or 
>470 msec (females), confirmed with [ADDRESS_95740] is of childbearing potential and lactating, pregnant (posit ive 
prerando mizat ion serum pregnancy test), or plans to beco me pregnant before participat ing in 
the study , during the study , or wi thin [ADDRESS_95741] has 1 or mor e laboratory values outside the normal range that are considered by [CONTACT_87831]; or the subject has any of the 
following at the Screening Visit: a serum creatinine value >1.[ADDRESS_95742], a total s erum  
total bilirubin value >1.5
×ULN, or a serum ALT or AST value >2× ULN. 
18.The subject has current history  of symptom atic orthostatic hypotension.
7.3 Excluded Medications, Supplements, and Dietary Products
The fo llowing are excluded:
Inhibitors for uridine 5' -diphosphate -glucuronosylt ransferase (UGT) enzymes (Probenecid 
and valproic acid) should be excluded for 14 days prior to dosing. 
Subjects m ust be instructed not to start any  medicati ons during the study , including 
over-the-counter products, without first consult ing with the invest igator. Occasional use of 
acetaminophen and aspi[INVESTIGATOR_87766].
Disallowed agents with CNS effects including but not limited to stimulants, lit hium, or 
monoamine -oxidase inhibitor antidepressant agents, dextromethorphan, memant ine, 
amantadine, anti psychoti cs medicat ions. See Table 7.afor details.
Sedative or hypnotic medication at equivalent doses greater than lorazepam [ADDRESS_95743] of any clinical assessments. 
Other agents with CNS effects may be allowed after consultation with the study sponsor or 
sponsor's designee .
Table 7.aprovides a list of excluded and allowed medicat ions. Thi s table however is not a 
comprehensive list and consultat ion with sponsor/representative might be warranted.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 41of 114
Protocol Incorporating Amendment No. 01 06October 2017
Table 7.a Excluded/Allowed Medications and Treatments
Drug ClassDisallowed (X) During the Study 
(sections without X indicate no restriction)
Chronic Use Epi[INVESTIGATOR_87767] (Probenecid and 
valproic acid)X X Wash -out for at least [ADDRESS_95744] 3 weeks prior to 
randomization and approval for patient 
inclusion by [CONTACT_3211]/representative
Psychotropic agents not otherwise specified 
(including but not limit ed to stimulants, 
tryptophan, melatonin)X X Wash -out of at least 3 weeks prior to 
randomization and approval for patient 
inclusion by [CONTACT_3211]/representative
Antipsychotics X X Excluded
Narcotic analgesics X X Except chronic use on stable dose for at least 
30 days prior to randomization 
Anticonvulsants (gabapentin, pregabalin or 
related drugs)X X Except chronic use on stable dose for at least 
[ADDRESS_95745] 
8 weeks prior to randomization and 
consultation with sponsor/representative
Herbal remedies, which are psychoactive (eg, St. 
Johns Wort, kava kava, valerian, ginkgo biloba, 
melatonin), OTC (e.g., caugh syrup)X X All OTC excluded. Patients should be 
instructed to consult with PI [INVESTIGATOR_87768]/hypnotics X X Except as described in Section 7.[ADDRESS_95746] 
14 days prior to randomization
MAOI=monoamine oxidase inhibitor, NSAIDs=nonst eroidal anti -inflammatory drugs, OTC=over -the-counter, 
RIMA=reversible inhibitor of monoamine oxidase type A, SNRI=serotonin –norepi[INVESTIGATOR_26331], 
SSRI=selective serotonin reuptake inhibitor.
7.[ADDRESS_95747] of any  clinical  assessments. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95748] from  the study  or study drug 
shoul d be recorded in the electronic case report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.1.18 .
1.Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires early 
termination because cont inued participat ion imposes an unacceptable risk to t he subject’s 
healt h or the subject is unwilling to continue because of the PTE or AE.
Liver function test (LFT) abnormalit ies:
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a sub ject’s laboratory profile has returned to 
norm al/baseline status, see Section 9.1.10 ), if the following circumstances occur at any 
time during study drug treatment:
–ALT or AST >8×ULN, or
– ALT or AST >5×ULN and persists for ≥2 weeks, or
–ALT or AST >3×ULN in conjunct ion with elevated total bilirubin >2×ULN or 
INR >1.5, or
–ALT or AST >3×ULN with appearance of fat igue, nausea, vomit ing, ri ght upper 
quadran t pain or tenderness, fever, rash, and/or eosinophilia (>5%).
ECG abnormalit ies
–QTcF > [ADDRESS_95749]’s health.
3.Lost to follow -up. The subject did not return to the clinic and attempts to contact [CONTACT_39783]. Attempts to contact [CONTACT_87832] s ubject’s source 
docum entati on.
4.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from  the study . The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal because of 
an AE should not be recorded in the “vo luntary withdrawal” category; similarly , lack of 
efficacy  should not be recorded in the “voluntary  withdrawal” category ).
5.Study  terminat ion. The sponsor, IRB, or regulatory agency terminates the study.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95750] is found to be pregnant.
Note: If the subject is found to be pregnant, the subject must be withdr awn immediately. The 
procedure is described in Sect ion9.1.[ADDRESS_95751] inal intolerance 
that cannot be ameliorated by  [CONTACT_87833].
8.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.[ADDRESS_95752]’s study  parti cipat ion at any t ime during the study when 
the subject meets the study terminat ion criteria described in Sect ion7.5. In addit ion, a sub ject ma y 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
[CONTACT_3170]. In addit ion, efforts should be made to perform all procedures scheduled for the 
Early Terminat ion Visit. Di scont inued or withdrawn subjects will not be replaced.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 44of 114
Protocol Incorporating Amendment No. 01 06October 2017
8.0 CLINICAL STUDY MATERIAL MANAGEMENT
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
In thi s prot ocol, the term  study  drug refers to all or any  of the drugs defined below.
[IP_ADDRESS] Study Drug
TAK -831 100 m g, 25 m g, and m atching placebo tablets will be provided as unmarked, round, 
yellow -red, film -coated tablets for oral administratio n. TAK -831 i s manufactured by [CONTACT_87834], Osaka, Japan.
The TAK -831 100 m g, 25 m g, and matching placebo tablets will be supplied in round, 
high-densit y polyethylene, 150 cc, round white bottles wit h child resistant caps. Each bottle will 
contain 180 tablets and will be l abeled wi th a single -panel, double -blind l abel. The label will 
include pertinent study  informat ion and appropriate country- specific regulatory caut ion 
statements.
[IP_ADDRESS] Sponsor -supplied Drug
Sponsor -supplied drugs referenced in other sections of the protocol inc lude the fo llowing: 
TAK -[ADDRESS_95753] be maintained every  working day .
8.1.3 Dose and Regimen
Treatment doses and regimens for the study  are provi ded i n Table 8.a.
Table 8.a Dose and Regimen
Treatment 
Group Dose Treatment Description
Active Placebo
Placebo Placebo BID Zero active tablets 3 TAK -831 placebo tablets
Low dose TAK -831 75 mg BID 3 TAK -831 25 mg tablets Zero TAK -831 placebo tablets
High dose TAK -831 300 mg BID 3 TAK -831 100 mg tablets Zero TAK -831 placebo tablets
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95754] according to the 
study  protocol .
All cases of overdose (with or without ass ociated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated 
with an overd ose will be documented on AE CRF(s) according to Section 10.0.
Serious adverse events (SAEs) associated with overdose should be reported according to the 
procedure outlined in Sect ion10.2.[ADDRESS_95755] ive response techno logy (IRT).
At the first and subsequent drug -dispensing visits, the invest igator or designee will access the IRT 
to request study drug for a subject. The medicat ion ident ificat ion (ID) number of the study drug to 
be dispensed will be provided by [CONTACT_6606].
8.[ADDRESS_95756] be recorded in the source documents and the same informat ion 
(except the time) must be recorded on the eCRF.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95757] should be filed in the 
investigator’s essent ial document file.
The invest igator or designee must maintain 100% accountabilit y for all sponsor -supplied drugs 
received and dispensed during his or her enti re parti cipat ion in the study . Proper drug 
accountabilit y includes, but is not limit ed to:
Continuously mo nitoring expi[INVESTIGATOR_82246]. 
Frequent ly verifying that actual inventory  matches d ocum ented inventory .
Verifying that the log is completed for the drug lot/medicat ion ID/j ob number used to prepare 
each dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accurately a nd legibly .
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IRT will include all required informat ion as a separate entry  for each subject to whom 
sponsor -supplied drug is dispensed.
The invest igator or designee must record the current inventory  of all sponsor -supplied drugs, 
TAK -831 100 m g, 25 m g, and m atching placebo tablets on a sponsor -approved drug 
accountabilit y log. The fo llowing informat ion will be recorded at a minimum: protocol number 
and tit le, name [CONTACT_45358], site ident ifier and number, descript ion of sponsor -supplied drugs, 
date and am ount di spensed including init ials, seal, or signature [CONTACT_39844], 
and the date and amount returned to the site by [CONTACT_423], in cluding the init ials, seal, or signature 
[CONTACT_79060]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95758] igator or 
designee will retain a copy  of the docum entati on regarding sponsor -supplied drug accountabilit y, 
return, and/or destruction, and originals will be sent to the sponsor or designee.
The invest igator will be notified of any expi[INVESTIGATOR_4057] n of sponsor -supplied 
drug during the study conduct. On expi[INVESTIGATOR_87769], the si te 
must com plete all  instructi ons outlined in the notification, including segregat ion of expi[INVESTIGATOR_45280] -supplied drug for return to the sponsor or its designee for destruction.
In the event of expi[INVESTIGATOR_57772] n of sponsor -supplied d rugalready  at the study  site, 
sponsor -supplied drugs may be relabeled with the new expi[INVESTIGATOR_87770]. In such cases, 
[COMPANY_005] or i ts desi gnee will  prepare addi tional labels, certificates of analyses, and all necessary  
docum entati on for com pletion of  the procedure at the sites. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-[ADDRESS_95759] identification number (site number plus subject number) will be assigned to each 
subject at the time that informed consent is obtained; this subject number will be used throughout 
the study. 
9.1.[ADDRESS_95760] has any significant 
conditions or diseases relevant to FRDA (including age at disease onset) that resolved at or prior to 
signing of informed consent. Ongoing conditions are considered concurrent medical conditions 
(see Section 9.1.9) .
Medication history information to be obtained includes any medication relevant to eligibility 
criteria.
9.1.3 Physical Examination Procedure
A baseline physical examination (defined as the assessment prior to the first dose of study drug) 
will consist of the following body systems: (1) ey es; (2) ears, nose, throat; (3) cardiovascular 
system; (4) respi[INVESTIGATOR_2133]; (5) gastrointestinal system; (6) dermatologic system; 
(7) extremities; (8) musculosk eletal sys tem; (9) nervous system; (10) lymph nodes; and (11) other. 
All subsequent physical examinations should assess clinically significant changes from the 
assessment prior to first dose examination.Property of [COMPANY_005]: For non-commeral HisH
be obtaine obta
eight, wight, w
be obtaine obta
eases reases r
formed cormed
on9.1.99.1. )
atioion hisn h
eria.ia.
[IP_ADDRESS]
A subject to the applicable Terms of Used. For d. For 
enever never 
studystudy , an
a subjeca subj
ct numbct num
ubject nuject n
CCI
TAK -[ADDRESS_95761] igator and recorded in the source 
docum ent and eCRF. All clinically significant findings/changes will be recorded as a pretreatment  
event (PTE) o r concurrent medical condit ion in the source document and in the eCRF described in 
Secti on10.0. 
On subsequent examinat ions, any  abnorm al change f rom the baseline physical examinat ion must 
be assessed as not clinically significant or clinically significant by [CONTACT_87835]. Any clinically significant change or new diagnosis as a result of a 
clinically significant change, as determined by [CONTACT_093], will be recorded as an AE in the 
source document and on the PTE/AE page of the eCRF. 
Neurol ogical exams: FARS n eurol ogical exam will subst itute for the standard neuro logical exams. 
FARS includes neuro logical signs that specifically reflect neural substrates affected in FRDA. 
Based on a neuro logical examinat ion, bulbar, upper limb, lower limb, peripheral nerve, and 
upright stabilit y/gait funct ions are assessed. See Section 9.1.7.
9.1.[ADDRESS_95762] weight and height measured while wearing indoor clothing and with shoes 
off (not a pplicable for subjects who are i n wheelchairs and their weight can be obtained by 
[CONTACT_87836]). The BMI is calculat ed at Screening using metric 
units wit h the formula below. Height is recorded in cent imeters without decimal places, and 
weight is collected in kilograms (kg) with [ADDRESS_95763]. BMI should be derived as fo llows:
Metri c BMI=       	(  )
       	( ) 
Note that although height is reported in centimeters, the formula uses meters for height; meters can 
be determined from cent imeters by [CONTACT_45322] 100. Thus, for example, if height=176 cm 
(1.76 meters) and weight=79.2 kg, then BMI=79.2/1.762=25.[ZIP_CODE] kg/m2.
The values shoul d be reported to [ADDRESS_95764] by  [CONTACT_45323]. Thus, in the above example BMI 
woul d be reported as 25.6 kg/m2.
9.1.5 Vital Sign Procedure
Vital signs will include oral body temperature, respi[INVESTIGATOR_697], sitting blood pressure (systolic and 
diastolic, resting more than 5 minutes), and pulse (beats per minute).
When vital signs are scheduled at the same t ime as blood draws, the blood draw will take priorit y 
and vital signs will be obtained wit hin 0.[ADDRESS_95765] measurement. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95766] (by  a trained operator/interviewer). If possible, the same interviewer should be 
used throughout the st udy for the same subject. All events such as suicidal ideat ions or behaviors 
shoul d be reported as AEs [36].
9.1.[ADDRESS_95767] assess the same subjects at each 
visit throughout the study , as m uch as possible. The time of the day  for the assessment should be 
consistent throughout the study as much as possible (eg, all mornings or a rough window of time). 
FARS neurological exam .
CGI-S (gl obal severi ty).
CGI-I (global improvement).
CGI-S (upper extremit y funct ional severit y).
CGI-I (upper extremit y funct ional improvement).
The fo llowing assessments will be administer by  [CONTACT_58673] (nurse, study  
coordinator) appointed by  [CONTACT_941] p rincipal invest igator. Each should have a record of successful 
completion of the required training, and have experience in FRDA or ataxia clinical trials. Each 
site shoul d also have a back -up administrator meeting the same requirements. However, it is 
strongly reco mmended that the same administrator assess the same subjects at the various visits 
throughout the study , as m uch as possible. The t ime of the day for the assessment should be 
consistent throughout the study as much as possible (eg, all mornings or a rough window of time). 
9-HPT.
T25FW (for ambulatory  subjects only. This will be done with the digital sensors for gait 
assessment).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 51of 114
Protocol Incorporating Amendment No. 01 06October 2017
LCLA test.
Digital speech assessment.
Digital balance and upper limb assessment.
C-SSRS.
The fo llowing assessments are p atient-reported outcome measures:
FARS ADL.
PGI-S (global severit y).
PGI-I (global improvement). 
PGI-S (upper extremit y functional severit y).
PGI-I (upper extremit y funct ional improvement).
9.1.[ADDRESS_95768] taken any medicat ion 
other than the study  drug (used from signing of informed consent through the end of the study ), 
and all medicat ion including vitamin supplements, over -the-counter m edicat ions, and oral herbal 
preparati ons, m ust be recorded in the eCRF. Docum entati on will include generic medicat ion 
name, dose, unit, frequency , route of administrati on, start and end dates, and reason for use.
9.1.9 Documentation of Concurrent Medical Conditions
Concurrent medical condit ions are those significant ongoing condit ions or diseases that are present 
at signing of informed consent. This includes clinically significant laboratory , ECG, or phy sical 
examinat ion abnormalit ies noted at the screening examinat ion. The condit ion (ie, diagnosis) 
shoul d be described.
9.1.10 Procedures for Cli nical Laboratory Samples
All samples will be collected in accordance with acceptable laboratory procedures. Details of these 
procedures and required safet y monitoring will be given in the laboratory  manual . Secti on9.4
describes procedures for specimen handling.
The tests that will be performed for each clinical laboratory specimen are listed in Table 9.a.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 52of 114
Protocol Incorporating Amendment No. 01 06October 2017
Table 9.a Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis
RBC s
WBC s with differential (% 
and absolute)
Hemoglobin
Hematocrit
Platelets ALT
Albumin
Alkaline phosphatase
AST
Total bilirubin
Total protein
Creatinine
Blood urea nitrogen
Creatine kinase
γ-Glutamyl transferase
Potassium
Sodium
Glucose
Chloride
Bicarbonate
CalciumpH
Specific gravity
Protein
Glucose
Blood 
Nitrite
Ketones
Bilirubin
Urobilinogen
Leukocyte esterase
Microscopic Analysis: (a)
Erythrocy tes/RBCs/high 
power field
Leukocytes/WBCs/high 
power field
Epi[INVESTIGATOR_1663], casts, etc
Serum Urine
Female subjects of childbearing potential only:
hCG (for pregnancy) at Screening and ET visit.
FSH Urine drug screen including amphetamines, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], cannabinoids, cocaine, methamphetamine, 
opi[INVESTIGATOR_858]. 
Female subjects of childbearing potential only:
hCG (for pregnancy) at Visits 2, 4, 5, and 6.
ET=early  termination, FSH=follicle -stimulating hormone, GGT= -glutamyl transferase, hCG=human chorionic 
gonadotropin, RBC=red blood cell, WBC=white blood cell.
(a) Microscopic examination of sediment to be performed only if the dipstick results are positive .
The central laboratory  will perform  laboratory  tests for hem atology, serum  chemistry , and 
urinalysis. The results of laboratory tests will be returned to the invest igator, who is responsible for 
reviewing and filing these results.
If subjects exp erience ALT or AST >3×ULN, follo w-up laboratory  tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed preferably 
within 48 to 72 hours and no later than 7 day s after the abnormalit y was noted (pl ease refer to 
Secti on10.2.3 for reporting requirements related to abnormal LFT results).
If ALT or AST remains elevated >3×ULN on these [ADDRESS_95769] details, and possible alternat ive 
etiologies. The abnormalit y shoul d be recorded as an AE (please refer to Section 10.2.3 for 
reporting requirements related to abnormal LFT results).
The invest igator or design ee is responsible for transcribing or attaching laboratory  resul ts to the 
eCRF. The invest igator will maintain a copy  of the laboratory  accredi tation and the reference 
ranges for the laboratory  used.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95770] dose of study  drug will  require clear and com plete 
docum entati on in the source do cuments as to the investigator’s assessment of not clinically 
significant before proceeding with enrollment or randomizat ion.
All clinically significant laboratory  abnorm alities must be recorded as a PTE/AE in the subject’s 
source documents and on the appr opriate eCRF. A clinically significant laboratory  abnorm ality 
that has been verified by [CONTACT_45324] y returns to an acceptable 
level or a satisfactory  explanat ion has been obtained. 
9.1.11 Contraception and Pregnancy Avoidance Procedure
[IP_ADDRESS] Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the study , and for [ADDRESS_95771] 
dose of study drug, nonsterilized** male subjects who are sexually act ive with a female partner of 
childbea ring potenti al* must use barri er contraceptio n (eg, condom wit h spermicidal cream or 
jelly). In addition, they  must be advised not to donate sperm during this period. The male subject 
must agree to advise the female partner to use additional contraception as shown in the list 
containing highly effective/effect ive contraception in Sect ion9.1.11.3 .
[IP_ADDRESS] Female Subjects and Their Male Partners
From  signing of informed consent, throughout the duration of the study , and for [ADDRESS_95772] 
dose of study  drug, female subjects of childbearing potential* who are sexually  active wi th a 
nonsterilized male partner** must use 2 highly effective/effect ive methods of contraception (fro m 
the list in Sect ion9.1.11.3 ). 
In addit ion they  must be advised not to donate ova during this period.
[IP_ADDRESS] Definitio ns and Procedures for Contraception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
* A wom an is considered a woman of childbearing potential, ie, fert ile, fo llowing menarche and 
until becoming postm enopausal  unless permanent ly sterile. Permanent sterilizat ion methods 
include hysterectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses 
for 12 months without an alternat ive medical cause. A high FSH level in the postmenop ausal range 
(FSH >40 IU/L) may be used to confirm a postmenopausal state in younger women (eg, those 
<45year old) or women who are not using hormonal contraception or hormonal replacement 
therapy . However, in the absence of 12 months of amenorrhea, a sing le FSH measurement is 
insufficient.
** Sterilized males should be at least [ADDRESS_95773] –bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95774] ive methods of contraception are defined as those, alone or in co mbinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correc tly). In this study, where devices containing hormones are excluded, the only acceptable 
methods of contraception ar e:
Nonhorm onal methods: 
–Intrauterine device.
–Bilateral tubal occlusio n. 
–Vasectomized partner (provided that partner is the sole sexual partn er of the study  
participant and that the vasectomized partner has received medical assessment of 
the surgi cal success. 
–True sexual abst inence, only if this is in line with the preferred and usual lifestyle o f 
the subject. True abstinence is defined as r efraining from  heterosexual intercourse 
during the ent ire peri od of  the study , from [ADDRESS_95775] dose.
–Cervical cap wit h spermicide and male condom.
–Diaphragm  with spermicide and m ale condom .
–Sponge with spermici de and m ale condom .
2.Doubl e-barrier methods are acceptable for this study  if used each time the subject has 
intercourse. 
Acceptable double -barrier methods (each time the subject has intercourse):
Cap (pl us spermicidal cream or jelly ) PLUS male condom  and s permicide.
Diaphragm  (plus spermicidal cream or jelly) PLUS male condom and spermicide.
3.Unacceptable methods of contraception are:
Horm onal methods.
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
4.Subjects will be provided with information on highly effect ive/effect ive methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 55of 114
Protocol Incorporating Amendment No. 01 06October 2017
consent form stating that they  understand the requirements for avoidance of pregna ncy, 
donati on of  ova, and sperm donat ion during the course of the study .
5.During the course of the study , regular urine hCG pregnancy tests will be performed only  for 
wom en of childbearing potential and all subjects (male and female) will receive continued 
guidance wi th respect to the avoidance of pregnancy  as part of the study  procedures. Such 
guidance shoul d include a reminder of the fo llowing:
a)Contraceptive requirements of the study .
b)Reasons for use of barrier methods (ie, condom) in males with pregnant p artners.
c)Assessment of subject compliance through questions such as:
i.Have you used the contraception consistent ly and correctly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregnancy test must be performed if the answer is “yes”)
iv.Is there a chance you could be pregnant ?
6.In addit ion to a negative serum or urine hCG pregnancy test at Screening, female subjects of 
childbearing potential m ust al so have confirmed menses in the mo nth before first dosing (no 
delayed menses), and a negat ive urine hCG pregnancy test on Day -1. Addi tional pregnancy 
testing will also be conducted during the study .
9.1.[ADDRESS_95776] is found to be pregnant d uring the study she should be withdrawn and any 
sponsor -supplied drug (TAK -831) shoul d be immedi ately discont inued. In addit ion, any 
pregnancies in the partner of a male subject during the study or within [ADDRESS_95777]’s partner.
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment informat ion, the individual blind should be broken by [CONTACT_3170]. 
Subjects rando mized to placebo need not be fo llowed.
If the female subject or female partner of a male subject agrees to the primary care physician being 
inform ed, the invest igator should notify the primary care physician that the female subject/female 
partner of the subject was participat ing in a clinical study  at the time she became pregnant and 
provi de details o f the study  drug the subject received (blinded or unblin ded, as applicable).
All pregnancies, including female partners of male subjects, in subjects on active study  drug will  
be fo llowed up to final outcome, using the pregnancy form. Pregnancies will remain blinded to the 
study  team . The outcom e, including any premature terminat ion, must be reported to the sponsor. 
An evaluat ion after the birth o f the child will also be conducted.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-[ADDRESS_95778] period for ECG recordings. Should technical 
difficulties occur during recording of the ECG, a reasonable attempt should be made to repeat the 
ECG shortly after the failed attempt.
The investigator (or a qualified observer at the study site who should have access to a cardiology 
consult) will manually interpret the ECG using 1 of the following categories: within normal limits, 
abnormal but not clinically significant, or abnormal and clinically significant. The time that the 
ECG was performed will be recorded. The following parameters will be calculated automatically 
by [CONTACT_87837]: heart rate, RR interval, PR interval, QT interval, 
QRS interval, QT interval with Bazett correction method, and QTcF interval. QTcF interval may 
be calcu lated manually by [CONTACT_3452]. The QTcF  interval is calculated as shown below:
     =	  
√   
One copy of the 12-lead ECG with the physician’s  signature [CONTACT_45360]. If the original ECG is printed on 
thermal paper, the ECG report must be photocopi[INVESTIGATOR_57777]. The photocopy will be filed with 
the original ECG in the source. The study site uses a fully validated ECG system. The investigator 
assessment is recorded electronically within this system.
All ECGs will be recorded at the time points detailed in the Schedule of Study Procedures 
(Appendix A) . 
9.1.[ADDRESS_95779] accesve acc
egories: wgories
significsignifi
rs will brs will b
RR interR inte
, and and QTQ
terval is erval i
=    
√√  √√y  √√√√ly
ysician’s cian’
in the apn the 
e photoce photo
e study sstudy
icallycally wyy
at the timt the t
e Colle Co
CCI
TAK-831
Study No. TAK-831- 1501 Page 57 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
9.1.15 PK Sample Collectio n and Analysis 
Serial blood samples (one 4-mL sample per scheduled time) for PK analysis of TAK-[ADDRESS_95780] recent dose will be recorded accurately in the eCRF.
Instructions for sample collection, pr ocessing and shipment are provided in the laboratory manual.
[IP_ADDRESS] Bioanalytical Methods
Plasma concentrations of TAK-831 will be measured by a validated high-performance liquid 
chromatography (HPLC) with tandem mass spectrometry method.
9.1.[ADDRESS_95781] ion and Analysis
Serial blood samples (one 6-mL sample per scheduled time) for PD (D- and L-serine) analysis of 
TAK-[ADDRESS_95782] meal will be recorde d on the source document and eCRF.
Instructions for sample collection, pr ocessing and shipment are provided in the laboratory manual.
[IP_ADDRESS] Bioanalytical Methods
Plasma concentrations of D- and L-serine will be measured by a validated HPLC with tandem 
mass spectrometry assay method. Property of [COMPANY_005]: For non-commercial use only and sed time)d time
utainers ctainers
A.
le coe collec
recordedrecord
processinrocess
dss
TAKAK--838
C) wiwiththiiih
mple Colle Co
amamples plemmmm
will be cll be
ng to theg to th
actualactual dl
ince lince l asa
InstrInsse CCI
TAK -[ADDRESS_95783] is wit hdrawn at the Screening Visit, the investigator should co mplete the eCRF. The 
IRT should be contact[CONTACT_39804] a n otificat ion of screen failure.
The primary  reason for screen failure is recorded in the eCRF using the following categories:
PTE/AE.
Did not m eet incl usion criteria or di d meet exclusion criteria (specify  reason). 
Significant protocol  deviat ion.
Lost to follow-up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other (specify reason).
Subject identificat ion numbers assigned to subjects who fail screening should not be used again. 
Subjects can only  be rescreened after approval by [CONTACT_456] . 
9.1.[ADDRESS_95784] Treatment Compliance
Subjects will be required to bring study drug containers/unused study drugs to each dispensing sit e 
visit. 
If a subject is persistent ly noncom pliant wi th the study  drug (80% of the allocated study  drug f or 
the period since the last visit), it may  be appropri ate to wi thdraw the subject from the study . All 
subjects should be reins tructed about the dosing requirement during study contacts. The authorized 
study  personnel conduct ing the re -education must document the process in the subject source 
records.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831- 1501 Page 59 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
9.3 Schedule of Observations and Procedures
The schedule for all study-related procedure s for all evaluations is shown in Appendix A.
Assessments should be completed at the designated visits.
9.3.1 Screening
Subjects will be screened as specified in  Appendix A.  Subjects will be screened in accordance with 
predefined inclusion and exclusion criteria as described in Section 7.0. See Section 9.1.18 for 
procedures for documenting screen failures.
9.3.2 Study Entrance/Randomization
Randomization will take place as described in  Appendix A.
If the subject has satisfied all of the inclusion criteria and none of the exclusion criteria for 
randomization, the sub ject should be randomized using the IRT, as described in Section 8.2. 
Subjects will be instructed on when to take the first dose of study drug as described in Section 6.1. 
The procedure for documenting screen failures is provided in Section 9.1.18.
9.3.[ADDRESS_95785]’s participation in the study. The 
subject should be returned to the care of a physician and standard therapi[INVESTIGATOR_82248].
9.4  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Useordance rdanc
nn9.[IP_ADDRESS]
the exclhe exc
T, as desT, as d
study druudy d
ed in Seced in S
cording trding
med at thd at t
hone Caone C
ll will bewill 
ceiving seiving
IntervInterv
ructureductur
[ADDRESS_95786] are shown in  Table 9.b.  
Table 9.b Approximate Blood Volume
Sample TypeSample Volume 
(mL)Number of Samples (a)
Total Volume 
(mL)Screening and 
Day -1 Treatment Period
Clinical laboratory (hematology and serum chemistry) 21 1 2 63
PK 4 1 5 24
PD (D- and L-serine) 6 1 3 24
Total approximate blood sampling volume (mL) 117
(a) Does not include blood draws at any unscheduled visits.
For each subject, the maximum volume of blood collected at any single visit is approximately 
[ADDRESS_95787] venipuncture is recommended for all blood co llections: if a catheter is used, then use the 
saline lock (catheter) for the blood draws without the extra tubing (eg, BD Insyte Autoguard Property of Take or non-commercial ucollectedollecte
Blood VBlood 
SaSmm
serum rumno
(D(D--and Land
Taof(a) Do(a) D
FUseCCI
CCI
TAK -831
Study No. TAK -831-1501 Page 61of 114
Protocol Incorporating Amendment No. 01 06October 2017
#381434 [needle] and ICU Medical, Inc Clave Connector #PM30- 2381 or similar). Any other 
method will need to be approved by [CONTACT_456]. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95788] who has 
signed inform ed consent to participate in a study  but pri or to administration of any study  drug; i t 
does not necessarily  have to have a causa l relationship wit h study  parti cipat ion.
10.1.[ADDRESS_95789] 
administered a drug; it does not necessarily have to have a causal relat ionship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  value), symptom, or disease temporally associated with the use o f a drug whether or not 
it is considered related to the drug.
10.1.[ADDRESS_95790] finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre- exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered PTEs or 
AEs.)
Necessitate therapeutic inter vention.
Requi re an invasive diagnostic procedure.
Requi re discont inuat ion or a change in dose of study  drug or a concomitant medicat ion.
Be considered unfavorable by [CONTACT_4168].
PTEs/AEs caused by a study  procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If a di agnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as a PTE(s) or as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG findings are only  considered to be PTEs or AEs if they 
are judged to be clinically significant (ie, if some action or intervent ion is required or if the 
investigator judges the change to be bey ond the range of normal physio logic fluctuati on). A 
laboratory  or ECG r e-test and/or continued mo nitoring of an abnormal value or finding is not 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 63of 114
Protocol Incorporating Amendment No. 01 06October 2017
considered an intervention. In addit ion, repeated or additional noninvasive testing for 
verification, evaluat ion or monitoring o f an abnormalit y is not consi dered an intervent ion.
Ifabnorm al laboratory  values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as a PTE or as an AE.
Pre-exist ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as PTEs or AEs. Baseline 
evaluat ions (eg, l aboratory  tests, ECG, X -rays) should NOT be recorded as PTEs unl ess 
related to study  procedures. However, if the subject experiences a worsening or complication 
of such a concurrent medical condit ion, the worsening or complicat ion should be recorded 
appropriately  as a PTE (worsening or complicat ion occurs before start of study  drug) or an AE 
(worsening or complicat ion occurs after start of study  drug). Invest igators should ensure that 
the event term recorded captures the change in the condit ion (eg, “worsening of…”).
If a subject has a pre -exist ing epi[INVESTIGATOR_39747] (eg, asthma, epi[INVESTIGATOR_002]) any 
occurrence of an epi[INVESTIGATOR_45284] a PTE/AE if the condit ion beco mes more 
frequent, serious or severe in nature. Investigators should ensure that the AE term recorded 
captures the change in the c ondition from Baseline (eg, “worsening of…”).
If a subject has a degenerat ive concurrent medical condit ion (eg, cataracts, rheumatoid 
arthri tis), worsening of the condition should only  be recorded as a PTE/AE if occurring to a 
greater extent to that which woul d be expected. Investigators should ensure that the AE term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
Worsening of PTEs or AEs:
If the subject experiences a worsening or complication of a PTE after the start of study  drug, 
the worsening or complication should be recorded as an AE. Invest igators should ensure that 
the AE term recorded captures the change in the PTE (eg, “worsening of…”).
If the subject experiences a worsening or complication of an AE after any  change in study
drug, the worsening or complicat ion shoul d be recorded as a new AE. Invest igators should 
ensure that the AE term recorded captures the change in the condit ion (eg, “worsening of…”).
Changes in intensit y of AEs /Serious PTEs:
If the subject experiences cha nges in intensit y of an AE/seri ous PTE, the event should be 
captured once with the maximum intensit y recorded.
Prepl anned procedures (surgeries or intervent ions):
Prepl anned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
inform ed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
perform ed early  (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95791] ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as PTEs or AEs, but should be documented in the sub ject’s source 
docum ents. Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):
Insufficient clinical response, efficacy, or pharmacologic act ion, should NOT be recorded as 
an AE. The invest igator must make the dist inction bet ween exacerbation o f pre-exist ing illness 
and lack of therapeutic efficacy.
Overdose:
Cases of overdose with any  medicati on wi thout m anifested si de effects are NOT considered 
PTEs or AEs, but instead will be docume nted on an Overdose page of the eCRF. Any 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.[ADDRESS_95792] medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATEN ING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPI[INVESTIGATOR_39749].
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Includes any event or synonym described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95793]
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_87771] a 
medicinal product
Convulsive seizure Pulmonary fibrosis 
Hepatic necrosis Spontaneous abortion / stillbirth and fetal death
Malignant hypertension Pulmonary hypertension
Torsade de pointes / ventricular fibrillation / ventricular 
tachycardiaAnaphy lactic shock
Acute renal failure
Toxic epi[INVESTIGATOR_194]/Stevens -Johnson syndrome Neuroleptic malignant syndrome / malignant hyperthermia
Note: Terms identified on the Medically Significant AE List represent the broad medical concepts to be considered as 
“Important Medical Events” satisfying SAE reporting requirements.
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and fo llowed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.5 Intensity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The event is transient and easily tolerated by [CONTACT_423].
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
10.1.6 Causality of AEs
The rel ationship of each AE to study  drug(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which po ssible involvement of the drug cannot be 
ruled out , although factors other than the drug, such as underlying diseases, complications, 
concomitant medications and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by [CONTACT_1604], such as underlying diseases, complications, 
concomitant medications and concurrent treatments.
10.1.7 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all PTEs and AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as Not Related. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 66of 114
Protocol Incorporating Amendment No. 01 06October 2017
10.1.8 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by  [CONTACT_14426]/or invest igator.
10.1.9 Stop Date 
The stop date of the AE/PTE is the date at which the subject re covered, the event resolved but with 
sequelae, or the subject died.
10.1.10 Frequency 
Epi[INVESTIGATOR_39751] c AEs/PTE (eg, vomit ing) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.11 Action Concerning Study Drug
Drug withdrawn –a study  drug i s stopped due to the particular AE.
Dose not changed –the particular AE did not require stoppi[INVESTIGATOR_007] a study  drug.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not Applicable –a study  drug was stopped for a reason other than the particular AE eg, the 
study  has been terminated, the subject died, dosing with study drug was already stopped before 
the onset of the AE.
Dose Reduced –the dose was reduced due to the particular AE.
Dose Interrupted –the dose was interrupted due to the particular AE.
10.1.12 Outcome
Recovered/Resolved – Subject returned to first assessment status with respect to the AE/PTE.
Recovering/Reso lving –the intensit y is lowered by  1 or m ore stages: the diagnosis or 
signs/symptom s has almost di sappeared; the abnormal laboratory  value improved, but has not 
returned to the normal range or to Baseline; the subject died from a cause other than the 
particular AE/PTE with the condit ion rem aining “recovering/reso lving”.
Not recovered/not resolved —there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, si gns/ symptom s or laboratory  value on the last day  of the observed 
study  period has got worse than when it started; is an irreversible congenita l ano maly; the 
subject died fro m another cause with the particular AE/PTE state remaining “Not 
recovered/not resolved”.
Reso lved with sequelae –the subject recovered from an acute AE/PTE but was left with 
perm anent/si gnificant impairment (eg, recovered fr om a cardi ovascular accident but with 
some persisting paresis.
Fatal  
–the AEs/PTEs which are considered as the cause of death. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 67of 114
Protocol Incorporating Amendment No. 01 06October 2017
Unknown –the course of the AE/PTE cannot be followed up due to hospi[INVESTIGATOR_1670]’s participati on in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
[IP_ADDRESS] PTE and AE Collection Period
Collect ion of PTEs will co mmence from the time the subject signs the informed consent to 
participate in the study  and cont inue until the subject is first a dministered study  drug (Vi sit 3) or 
until screen failure. For subjects who discont inue prior to study drug administration, PTEs are 
collected unt il the subject discont inues study  parti cipat ion.
Collect ion of AEs will co mmence fro m the time that the subject is first administered study  drug 
(Visit 3). Routine collect ion of AEs will continue unt il the fo llow-up phone call .
[IP_ADDRESS] PTE and AE Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have y ou been feeling since y our l ast visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing a 
serious PTE m ust be monitored until the symptoms subside and any clinically relevant changes i n 
laboratory  values have returned to Baseline or there is a sat isfactory  explanati on for the change. 
Nonserious PTEs, related or unrelated to the study  procedure, need not to be fo llowed-up for the 
purposes of the protocol.
All subjects experiencing AEs, w hether considered associated with the use of the study  drug or 
not, m ust be m onitored until  the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the invest igator concludes that the event is related to the drug treatment. The 
following informat ion will be documented for each event:
1.Event term .
2. Start and sto p date. The timing o f the AE in relat ion to first dose of study drug (predose or 
postdose) will be indicated if the AE occurs on the first day  of dosing.
3.Frequency.
4.Intensit y.
5.Invest igator’s opi[INVESTIGATOR_3078] n of the causal relat ionship between the event and administ ration of study 
drug(s) (related or not related) (not completed for PTEs).
6.Invest igator’s opi[INVESTIGATOR_3078] n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
7.Action concerning study  drug (not applicable for PTEs).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95794] for medical 
evaluat ion shoul d be undertaken. Through this fo llow-up if it is determined that an AE not 
previously reported has been identified, normal reporting requirements should be applied.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A [COMPANY_005] SAE form must be co mpleted, in English, and signed by [CONTACT_57801] [ADDRESS_95795] onset or notificat ion of t he event. The informat ion should be completed as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  drug.
Causalit y assessment.
The SAE form should be transmitted within [ADDRESS_95796] elevated >3 ×ULN on [ADDRESS_95797] >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should b e recorded as an SAE and reported 
as per Secti on10.2.[ADDRESS_95798] d etails and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease or medical history /concurrent m edical  condi tions. Fo llow-up laboratory  
tests as described in Sect ion9.1.[ADDRESS_95799] be completed and transmitted with the [COMPANY_005] SAE form (as per Section 10.2.2 ).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95800] report becomes available at a later date, the 
investigator should co mplete a fo llow-up SAE form (or provi de other wri tten docum entati on) and 
fax it within 24 hours of receipt . Copi[INVESTIGATOR_87772] m the hospi [INVESTIGATOR_11533] (eg, ECGs, 
laboratory  tests, di scharge summary , postm ortem  resul ts) shoul d be sent to the addressee, if 
requested.
All SAEs should be fo llowed up until reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.[ADDRESS_95801] ions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory authorities, including the FDA, European 
Medicines Agency, invest igators, and IRBs, as applicable, in accordance with nat ional regulat ions 
in the countri es where the study  is conducted. Relative to the first awareness of the event by/or 
further provisio n to t he sponsor or sponsor’s designee, S[LOCATION_003]Rs will be submitted to the regul atory 
authori ties as expedited report within 7 days for fatal and life -threatening events and 15 days for 
other serious events, unless otherwise required by [CONTACT_87838]. The sponsor will also 
prepare an expedited report for other safet y issues where these might materially  alter the current 
benefit -risk assessment of a study  drug/sponsor supplied drug or that would be sufficient to 
consider changes in the study drug/sponsor supplied drug administration or in the overall conduct 
of the tri al. The study  site also will  forward a copy of all  expedi ted reports to hi s or her IRB.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95802] not been any safet y findings that indicate the 
need for an independent Data Monitoring Co mmit tee(DMC) . 
However, in addit ion to the ongoing review of blinded safet y data by  [CONTACT_87839] , the sponsor willestablish an internal DMC independent of the 
study  and project team to periodically review unblinded safet y data during conduct of this study to 
complement the routine safet y monitoring approach for compounds at this stage of development. 
The funct ions an d procedures of the committee will be outlined in a DMC Charter . 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 71of 114
Protocol Incorporating Amendment No. 01 06October 2017
12.0 DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_85958]. 
AEs, PTEs, medical history , and concurrent m edical  condi tionswill be coded using the Medical 
Dictionary for Regulatory  Activities (MedDRA). Drugs will be coded using the World Health 
Organizat ion Drug Di ctionary.
12.1 CRFs (Electronic)
Com pleted eCRFs are required for each subject who signs an informed consent.
The spon sor or i ts designee will supply study  sites wi th access to eCRFs. The sponsor will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study to the sponsor and regulatory authorities. 
eCRFs must be completed in English. Data are transcribed directly  onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and ques tionable values. Queri es may  be issued by [CONTACT_1748] (or designees) and will be answered by [CONTACT_779]. 
The principal invest igator must review the eCRFs for completeness and accuracy and must e-sign 
the appropriate eCRFs as indicated. Furthermore, the invest igator must retain full responsibilit y 
for the accuracy  and authent icity of all data entered on the eCRFs.
The eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic 
visits by [CONTACT_3552]. The spo nsor or its designee will be permitted to review the 
subject’s medical and hospi[INVESTIGATOR_87773] o f the eCRFs. The 
completed eCRFs are the sole property  of the sponsor and should not be made available in any 
form to thi rd parti es, except for authorized representatives o f appropri ate governmental healt h or 
regul atory  authori ties, wi thout wri tten permissio n of the sponsor. 
After lock of the clinical study database or submissio n of the eCRFs to the sponsor, any change o f, 
modificati on of , or addi tion to the data on eCRFs should be made by  [CONTACT_87840] o f 
change and modificat ion records of eCRFs (Data Clarification Form) provided by [CONTACT_456]. The 
principal investigator [INVESTIGATOR_87774], and 
must si gn and date the form .
12.[ADDRESS_95803] igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dat ed informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable e valuat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
docum entati on printed on degradable thermal sensitive paper should be photocopi[INVESTIGATOR_47355] h the original in the subject’s chart to ensure long term legibilit y. Furtherm ore, The 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 72of 114
Protocol Incorporating Amendment No. 01 06October 2017
International Council for Harmonisat ion (ICH) E6 Section 4.9.[ADDRESS_95804] igator to retain 
essent ial documents specified in ICH E6 (Section 8) until at least [ADDRESS_95805] igation is discont inued and regulatory authorities 
are notified. In addit ion, ICH E6 Section 4.9.5 states that the study records shoul d be retained unt il 
an amount of time specified by  [CONTACT_87841] a time specified in the 
study  site agreement between the investigator and sponsor.
Refer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact [CONTACT_4182] m the sponsor before disposing of any 
such documents.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 73of 114
Protocol Incorporating Amendment No. 01 06October 2017
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized prior to unblinding of treatm ent 
assignments. This docum ent will provi de further details regarding the definit ion of analysis 
variables and analysis methodology  to address all study  objectives.
A blinded data review will be conducted prior to unblinding of treatm ent assignments. This review 
will assess the accuracy and completeness of the study  database, subject evaluabilit y, and 
appropriateness of the planned statist ical methods.
Multiplicity across doses will be controlled for the primary  endpoint as descr ibed in 
Secti on13.1.3.1 . Mul tiplicity will not be controlled for the secondary  endpoints.
13.1.1 Analysis Sets
[IP_ADDRESS] Full Analysis Set
The full analysis set ( FAS) will include all subjects who were randomized and received at least 
1dose of the study  drug for the treatment period. In FAS efficacy  summaries, subjects will be 
analyzed by [CONTACT_87842].
[IP_ADDRESS] Safety Analysis Set
The Safety Analysis Set will include all randomized subjects who receive at least 1 dose of 
double -blind study medication. In safety summaries, subjects will be analyzed according to the 
treatment they received.
[IP_ADDRESS] PD Analysis Set
The PD analysis set will consist of sub jects who receive at least [ADDRESS_95806] corresponding 1 postdose plasma concentration measurement.
[IP_ADDRESS] Per-Protocol Set
The per -protocol set will include all FAS subjects who had no major protocol vio lations.
13.1.[ADDRESS_95807], stratified by [CONTACT_87843]. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 74of 114
Protocol Incorporating Amendment No. 01 06October 2017
13.1.3 Efficacy Analysis
[IP_ADDRESS] Primary Efficacy Analysis
Theprimary  endpoint for thi s study  is the change from  Baseline to Week 12 in the inverse of the 
time to complete the 9- HPT (9 -HPT-1) after treatment with TAK -831, com pared wi th placebo.
The primary analysis o f change fro m Baseline in [ADDRESS_95808] imates fro m a 
mixed model for repeated measures (MMRM) with Baseline 9 -HPT-1as a covariate; pooled site, 
visit, treatment, and ambulatio n status (randomizatio n factor) as fixed factors; and 
treatm ent-by-visit and [ADDRESS_95809] at each time point for 
each treat ment is allowed to vary  freely and an unstructured covariance matrix is assumed. If the 
model does not converge, other covariance structures (unstructured, compound symmetry , 
2-Toeplitz, etc) will be considered. A suite of appropriate sensit ivity analyses will be specified in 
the SAP.
Since 2 doses of TAK -831 are compared to placebo, mult iplicit y will  be controlled at the Holm’s 
method. The dose with the smaller p -value will be tested at the one -sided 0.[ADDRESS_95810] acebo.
Subgroup analyses will be conducted according to ambulat ion status and Baseline D -serine 
concentration.
[IP_ADDRESS] Secondary Efficacy Analysis
Analysis of secondary efficacy endpo ints will be based on the FAS. For these endpo ints,which are 
continuous change fro m Baseline endpo ints, com parisons between TAK -[ADDRESS_95811] and summarized by [CONTACT_87844] .
Individual concentration -time data will be pooled to describe the populat ion PK of TAK -831. As 
data permit, a nonlinear mixed effects modeling approach (NONMEM software) will be used to 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95812] asma 
concentrations and drug response (D- or L-serine plasma levels and/or selecte d measures of 
efficacy) will be explored. As appropriate, historical data may be used in this analysis to increase 
the robustness of the model and precisio n of estimated parameters. Details o f the modeling 
approach will be provided in a separate analysis p lan, and the results of these analyses may  be 
reported separately .
13.1.[ADDRESS_95813] regimens 
(high dose, low dose and placebo) will be made and the CIs for the difference in the LS means will 
be constructed for selected time po ints. Addit ional details and further analyses will be specified in 
the SAP. (See also Section 13.1.4 .)
13.1.6 Safety Analysis
Analysis of safet y variables will be based on the safet y analysis set.
[IP_ADDRESS] Analysis of AEs
All AEs will be coded using MedDRA. Data will be summarized using preferred term and primary 
system  organ class. AEs that are reported more than once by a subject during the same period will 
be counted only once for that subject and period at the maximum severit y.
[IP_ADDRESS] Analysis of Other Safety Assessments
Other safet y endpo ints include:
Laboratory  values.
Vital signs.
Weight.
ECGs.
Physical examinat ion findings.
Absolute values and changes fro m Screening/Baseline in clinical laboratory  tests, vi tal signs, 
weight and ECG param eters will be summarized for each treatment group at all visits assessed 
using descrip tive techniques. Physical examinat ion findings will also be summarized for each 
treatm ent group. Values outside the reference ranges and markedly  abnorm al laboratory  values 
will be flagged and tabulated.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 76of 114
Protocol Incorporating Amendment No. 01 06October 2017
13.1.7 Responder Analysis
A responder analysis to estimate the responder definit ion/thresho ld for the 9 -HPT will be 
conducted. The methods used will be based on recommended methods presented in the FDA PRO 
guidance [28].
The m ain responder analysis will use patient global rat ings, as measured by [CONTACT_87792] -I, on the 
change in upper limb funct ion as the anchor. Other patient and clinician global ratings for upper 
limb funct ion (PGI-S, CGI -S, CGI -I) will be candidate measures as supportive anchors. All 
anchors will be reviewed for appropriateness. FARS ADL items 3 to 5 will also be considered. 
The basis o f the thresho ld for meaningful change in the main responder analysis will correspond to 
the mean (or median) change score on the [ADDRESS_95814] imate[37-39] .
Addit ional analyses will e xplore if a pat ient-reported improvement in upper limb funct ion is 
meaningful fro m the patient perspecti ve, as captured by  [CONTACT_87845] t Interview. 
Applicat ion of the main and supportive responder definit ions will be done by  [CONTACT_87846] 9 -HPT between TAK -831and placebo groups at Week 12.
Responder analyses will be replicated for each time point assessed (eg, Weeks 2 and 7).
13.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3 Determination of Samp le Size
Approximately  65 subjects will be randomized in a 2:1:2 ratio for the placebo, low, and high dose 
respectively . It is assumed that approximately 60 subjects (92%) will co mplete [ADDRESS_95815] size of 0.6 for each dose, there will be 77% power for at least [ADDRESS_95816] acebo and 54 % power for both doses (overall alpha=0.10, 1 -sided). 
Validated software (EAST 6.3, Cy tel Inc.) was used to determine the power. The effect size was 
chosen based on the premise that a treatm ent effect equivalent to prevent ing or reversing 2 years of 
declin e due to FDRA woul d be clinically  meaningful . Using published data [
19], the target effect 
size is approximately  0.6 f or the 9 -HPT.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95817] 
research organizat ion and by [CONTACT_87847] (IEC).
All aspects of the study and its documentation will be subject to review by [CONTACT_4209]’s 
designee (as long as blinding is not jeopardized), including but not limited to the Investigator’s 
Binder, study  drug, subject m edical records, informed consent document ation, docum entati on of  
subject authorizat ion to use personal healt h information (if separate fro m the inform ed consent 
forms), and review o f eCRFs and associated source documents. It is important that the invest igator 
and other study  personnel are availab le during the mo nitoring visits and that sufficient time is 
devoted to the process.
14.[ADDRESS_95818] to study subjects. Should other unexpecte d circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a p rospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions noted i n the subject’s source documents. In the 
event of a significant deviat ion, the site should notify the sponsor or its designee (and IRB or ethics 
committee, as required). Significant deviat ions include, but are not limited to, those that invo lve 
fraud or misconduct, increase the healt h risk to the subject, or confound interpretation of primary  
study  assessment. 
The invest igator should document all protocol deviations via the eCRF.
14.[ADDRESS_95819] the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, the re is the possibilit y that this study may be inspected by [CONTACT_17513], including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contact[CONTACT_4190] a regulatory  body , the sponsor should be notified 
immediately . The investi gator guarantees access for qualit y assurance auditors to all study  
docum ents as described in Sect ion14.1.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95820] for the individual participants (ie, subjects) 
according to the protocol, the eth ical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable regional regulatory  requi rements and align his or her conduct in 
accordance with the “Responsibilit ies of the Investigator” that are listed in Appendix B. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.[ADDRESS_95821] concerns should instead provide a Federal Wide Assurance Number or comparable 
number assigned by  [CONTACT_87848].
The sponsor or designee will su pply relevant documents for submissio n to the respective IRB for 
the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy of the 
inform ed consent form , a copy  of the Exi t Intervi ew protocol , and, if applicable, subject 
recrui tment materials and/or advertisements and other documents required by [CONTACT_87849], must be submitted to a central or local IRB for approval. The IRB’s written 
approval  of the protocol  and subject informed consent must be obtained and submi tted to the 
sponsor or designee before commencement of the study (ie, before shipment of the 
sponsor -supplied drug or study  specific screening activit y). The IRB approval must refer to the 
study  by [CONTACT_39819], number, and versio n date; iden tify versio ns of other documents 
(eg,informed consent form) reviewed; and state the approval date. The sponsor will notify site 
once the sponsor has confirmed the adequacy o f site regulatory  docum entati on and, when 
applicable, the sponsor has received per missio n from competent authori ty to begin the study . 
Study  sites m ust adhere to all requirements st ipulated by [CONTACT_87850]. This may include 
notification to the IRB regarding protocol amendments, updates to the informed consent form, 
recrui tment materials intended for viewing by  [CONTACT_1766], l ocal safet y reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  [CONTACT_87851], and submissio n of the invest igator’s final status report to IRB. Al l IRB approvals 
and relevant documentation for these items must be provided to the sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by [CONTACT_87852].
15.[ADDRESS_95822] Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95823] authori zation form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the prep aration, content, and IRB or IEC approval of the 
inform ed consent form  and if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by [CONTACT_39821].
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and writ ten form  whenever possible and in the 
manner deemed appropriate by [CONTACT_4186]. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the st udy. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by  [CONTACT_423], or the subje ct’s l egally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and prior to subject entering 
into the study; however, the sponsor may  allow a designee of the inves tigator to si gn to the extent 
permitted by  [CONTACT_1289].
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
inves tigator m ust docum ent the date the subject signs the informed consent in the subject’s 
medical record. Copi[INVESTIGATOR_1681], the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by [CONTACT_39822]’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained should be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-[ADDRESS_95824]’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the sponsor’s clinical trial database or documentation via a subject identification number. As 
permitted by [CONTACT_1763], limited subject attributes, such as sex, age, or date 
of birth, and subject initials may be used to verify the subject and accuracy of the subject’s unique 
identification number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor 
requires the investigator to permit the monitor or the sponsor’s designee, representatives from any 
regulatory authority (eg, FDA, Medicines and Healthcare products Regulatory Agency, 
Pharmaceuticals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs to review the subject’s original medical records (source data or documents), 
including, but not limited to, laboratory test result reports, ECG reports, admission and discharge 
summaries for hospi[INVESTIGATOR_1684] a subject’s study participation, and autopsy 
reports. Access to a subject’s original medical records requires the specific authorization of the 
subject as part of the informed consent process (see Section 15.2) .
Copi[INVESTIGATOR_87775] (ie, s ubject name, address, and other identifier fields 
not collected on the subject’s eCRF).
15.[ADDRESS_95825] results and all data derived by 
[CONTACT_87853]. During and after  the study, only the sponsor may make study 
information available to other study investigators or to regulatory agencies, except as required by 
[CONTACT_6617]. Except as otherwise allowable in the study site agreement, any public disclosure 
(including publicly accessible websites) related to th e protocol or study results, other than study 
recruitment materials and/or advertis ements, is the sole responsibility of the sponsor.
The investigator needs to obtain a prior written approval from the sponsor to publish any 
information from the study externally such as to a professional association.
15.4.2 Clinical Tria l Registration
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulations and guidance, [COMPANY_005] will, at a minimum register all 
interventional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly accessible websites before start of study, as defined in [COMPANY_005] Policy/Standard. [COMPANY_005] Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Ter  of Useotection otectio
y be linkbe lin
numbernumbe
h as sex,as sex
of tthe suhe 
with thiswith t
esignee, ignee
ducts Reucts R
or’s desig’s desi
al recordl recor
ports, ECrts, E
ng a subjg a sub
records rcords
ess (see S(se
that are hat ar
mmoved (oved
F).).
ure, andre, an
nd Discl Disc
obliged tliged
from the om th
vailable vailab
ulation. Eation
ng publig pub
tment mtment 
he inveshe inv
informinfo
1CCI
TAK -[ADDRESS_95826] igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, [COMPANY_005] will assist callers in lo cating study  sites cl osest to their homes by 
[CONTACT_39824], address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact [CONTACT_4203], they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor. 
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site.
15.4.[ADDRESS_95827] the results of clinical trial son C linicalTrials.gov and/or other publicly accessible 
websites, as required by [CONTACT_39825]/Standard, applicable laws and/or regulat ions.
15.[ADDRESS_95828] is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact [CONTACT_39826]’s designee.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 82of 114
Protocol Incorporating Amendment No. 01 06October 2017
16.0 REFERENCES
1.Sacchi S. D -Serine metabo lism: new i nsights into the modulation o f D-amino acid oxidase 
activit y. Biochem  Soc Trans 2013;41(6):1551 -6.
2.Kakegawa W, Miyoshi Y, Hamase K, Matsuda S, Matsuda K, Kohda K, et al. D -serine 
regul ates cerebellar LTD and motor coordination through the delta2 glutamate receptor. Nat 
Neurosci 2011;14(5):603-11.
3.Saigoh K, Matsui  K, Takahashi K, Ni shikawa T, Wada K. The stereo -specific effect of 
D-serine ethylester and the D- cycloserine in ataxic mutant mice. Brain Res 1998;808(1):[ADDRESS_95829] ions. In: Fredericks C, Saladin LK, 
editors. Pathophy siology of  the Motor Sy stems: Principles and Clinical Presentations. 
Philadelph ia, PA: F. A. Davis; 1996.
5.Wilson CL, Fahey MC, Corben LA, Co llins VR, Churchyard AJ, Lamont PJ, et al. Qualit y of 
life in Friedreich ataxia: what clinical, social and demographic factors are important? Eur J 
Neurol  2007;14(9):1040-7.
6.Pando lfo M. Fri edreich’s ataxia. In: Wells RD, Ashizawa T, editors. Genetic Instabilit ies & 
Neurol ogical Diseases. Burlington, [LOCATION_005]: Academic Press; 2006; Chapter 17, p. 
277-96.
7.Pando lfo M. Fri edreich ataxia: the clinical pi[INVESTIGATOR_1103]. J Neurol 2009;[ADDRESS_95830] 1:3 -
8.
8.Labuda M, Labuda D, Miranda C, Poirier J, Soong BW, Barucha NE, et al. Unique origin and 
specific ethnic distribut ion of the Friedreich ataxia GAA expansio n. Neurology  
2000;54(12):2322 -4.
9.Campuzano V, Montermini L, Molto MD, Pi[INVESTIGATOR_87776] L, Cossee M, C avalcanti F, et al. 
Friedreich's ataxia: autosomal recessive disease caused by [CONTACT_87854] n. Sci ence 1996;271(5254):1423-7.
10.Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, et al. Frataxin is 
reduced i n Friedreich ataxia pat ients and is associated with mitochondrial membranes. Hum 
Mol Genet 1997;6(11):[ADDRESS_95831] C, Penet C, et al. Clinical and genet ic 
abnorm alities in pat ients with Friedreich's ataxia. N Engl J Med 1996;335(16):1169-75.
12.Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunt i P. Clinical features of Friedreich's 
ataxi a: classical and aty pi[INVESTIGATOR_87777]. J Neurochem 2013;[ADDRESS_95832] 1:103-17.
13.Koeppen AH, Mazurkiewicz JE. Friedreich at axia: neuropathology revised. J Neuropathol Exp 
Neurol  2013;72(2):78-90.
14.Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, et al. Emerging therapi[INVESTIGATOR_87778]'s ataxia. Neurodegener Dis Manag 2016;6(1):49 -65.
15.Akbar U, Ashizawa T. Ataxia. Neurol Clin 2015;33(1):225 -48.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 83of 114
Protocol Incorporating Amendment No. 01 06October 2017
16.Sham PC, Gottesman, II, MacLean CJ, Kendler KS. Schizophrenia: sex and familial 
morbidity. Psychiatry  Res 1994;52(2):[ADDRESS_95833]. Psy choses and cluster A personalit y 
disorders in offspring o f schizophrenic parents at 23 years of fo llow-up. Arch Gen Psychiatry  
1995;52(10):857 -65.
18.Radi ZA, Stewart ZS, Grzemski FA, Bobrowski WF. Renal p athophysio logic rol e of corti cal 
tubul ar inclusi on bodi es. Toxi col Pathol  2013;41(1):[ADDRESS_95834] S, Strawser C, et al. Progression of Friedreich 
ataxi a: quant itative characterization over 5 y ears. Ann Clin Tra nsl Neurol  2016;3(9):[ADDRESS_95835] J, Silberberg N, Iversen I, Cummings R. Hand strength and dexterit y. Am J 
Occup Ther 1971;25(2):77-83.
21.Rehabilitat ion Measures Database. Rehab measures: nine -
hole peg test. Published 30 October 
2010. Upd ated 24 May 2016. Accessed 12 March 2017. Available at: 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=925.
22.Feys P, Lamers I, Francis G, Benedict R, Phillips G, LaRocca N, et al. The Nine- Hole Peg Test 
as a m anual  dexteri ty performance measure for mult iple sclerosis. Mult Scler 
2017:1352458517690824.
23.Corben LA, Tai G, Wilso n C, Collins V, Churchyard AJ, Delat ycki MB. A co mpar ison of 
three m easures of upper limb funct ion in Friedreich ataxia. J Neurol 2010;257(4):[ADDRESS_95836] of 
finger dexterit y. Occup Ther J Res 1985;5(1):24-38.
25.Oxford Gri ce K, Vogel  KA, Le V, Mi tchell A, Muniz S, Vollmer MA. Adult norms for a 
commercially  available Nine Ho le Peg Test for finger dexterit y. Am J Occup Ther 
2003;57(5):[ADDRESS_95837] (9 -HPT) across the age span. J Hand Ther 2015;28(1):53 -9; qui z 60.
27.Lynch DR, Farmer JM, Wilso n RL, Balcer LJ. Performance measures in Friedreich ataxia: 
potenti al utility as clinical  outcom e tool s. Mov Di sord 2005;20(7):777 -82.
28.Psychopharm acolgic Drugs Advisory  Committee (PDAC) meet ing of the June 9 -10, 2009. 
Departm ent of Healt h and Hum an Services, Public Health Service, Food and Drug 
Administrati on, Center for Drug Evaluat ion and Research. 08 May  2009.
29.Subramo ny SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, et al. Measuring 
Friedreich ataxia: Interrater reliabilit y of a neurol ogic rating scale. Neurology  
2005;64(7):1261 -2.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95838], Farmer JM, Tsou AY, Perlman S, Subramony SH, Gomez CM, et al. Measuring 
Friedreich ataxia: co mplementary  features of examinat ion and performance measures. 
Neurol ogy 2006;66(11):1711-6.
31.Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO, et al. Measuring 
the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord 
2010;25(4):[ADDRESS_95839] AJ, Delat ycki MB. How is disease progress in 
Friedreich's ataxia best measured? A study o f four rating scales. J Neurol Neurosurg 
Psychiatry  2007;78(4):411 -3.
33.Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a 
multiple scl erosi s functi onal com posite as a clinical tri al outcome m easure. Brain 1999;122 ( 
Pt 5):[ADDRESS_95840] ion in pat ients with Friedreich ataxia. J Neuroophthalmo l2002;22(4):270 -4.
35.Vogel  AP, Wardrop MI, Fol ker JE, Synofzik M, Corben LA, Delat ycki MB, et al. Voice in 
Friedreich Ataxia. J Voice 2017;31(2):243 e9 -e19.
36.Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia -Suicid e Severit y Rat ing Scale: init ial validit y and internal consistency findings fro m 
three m ultisite studi es wi th adol escents and adults. Am J Psychiatry  2011;168(12):1266-77.
37.Norm an GR, Sl oan JA, Wyrwich KW. Interpretation of changes in health- related qua lity of 
life: the remarkable universalit y of half a standard deviat ion. Med Care 2003;41(5):[ADDRESS_95841]. Interpreting pat ient-reported 
outcom e resul ts: US FDA gui dance and em erging methods. Expert Rev Pharm acoecon 
Outcom es Res 2011;11(2):163 -9.
39.Wyrwich KW, Krishnan S, Poon JL, Auguste P, von Maltzahn R, Yu R, et al. Interpreting 
important health -related qualit y of life change using the Haem -A-QoL. Haem ophilia 
2015;21(5):578 -84.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 85of 114
Protocol Incorporating Amendment No. 01 06October 2017
Appendix ASchedule of Study Procedures
Screening Baseline and Treatment Period Phone Exit 
InterviewSafety 
Phone 
Follow -upEarly 
Termination 
Visit
Clinic Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Study DayWithin 28 
days -1 1 (a)2-13
(home)14
(±3 ) 
days15-48 
(home)49
(±3 )
days50- 83
(home)84
(±2 )
days≤[ADDRESS_95842] 
dose
Informed consent X
Randomization X
Inclusion/exclusion criteria X X X
Demographics and medical 
historyX
Medication history X
Concurrent medical 
conditio ns X
Physical examination X X X
Height and BMI (Screening 
only), weight X X X
Clinical laboratory tests (b) X X X X
Urine drug screen X
FSH X
Urinaly sis X X X X
Pregnancy test (hCG) (c) X X X X X X
Footnotes are on last table page.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831-1501 Page 86 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
Screening Baseline and Treatment Period Phone Exit 
InterviewSafety 
Phone 
Follow-upEarly 
Termination 
Visit
Clinic Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Study DayWithin 28 
days -1 1 (a)2-13
(home)14
(±3) 
days15-48 
(home)49
(±3) 
days50- 83
(home)84
(±2) 
days≤[ADDRESS_95843] 
dose
ECG X X X
FARS Functional Staging for AtaxiaX
Vital signs (a) X X XXXX X
C-SSRS X X X X X X
Concomitant medications X X XXXX X
Dispense study medication 
(d)XXX
Study drug dosing (d) XXXXXX X  ( e )
PTE/AE assessment (a) XXXXXXXX X X X
Interim phone calls (f) X X X
PK blood collection (h) X XXXX X
PD blood collection (D- and 
L-serine) (i)X XXX X
9-HPT (j) (k) (l) X X XXXX X
F A R S  A D L  ( j ) X XXXX X
FARS-neuro (j) (l) X X XXXX X
T25FW and digital gait with 
sensors (j) (l)X X XXXX X
Footnotes are on last table page.
Property of [COMPANY_005]XXda: For non-c ercial use only and subject to the applicable Terms of Usele
Phone Exhone 
IntervInteab
apit 66aapapap
-8 383
(home)ome848
(±e
to
ecbjubjbjbj
nbj
Xnnndanaaaa
nlyoXoooo
XXlllualXXiaaaa
XXer
Xcn
XXn
FoFoFoFoFoXX:FFF
da
TaTaTaTaable page.ble pagCCI
TAK -831
Study No. TAK -831-1501 Page 87of 114
Protocol Incorporating Amendment No. 01 06October 2017
Screening Baseline and Treatment Period Phone Exit 
InterviewSafety 
Phone 
Follow -upEarly 
Termination 
Visit
Clinic Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Study DayWithin 28 
days -1 1 (a)2-13
(home)14
(±3) 
days15-48 
(home)49
(±3) 
days50- 83
(home)84
(±2) 
days≤[ADDRESS_95844] 
dose
Digital speech assessment 
(j) (l)X X X X X X X
Digital balance and upper 
limb assessment (j) (l)X X X X X X X
Low contrast letter acuity  (j) 
(l)X X X X X X
CGI-S (overall severity) (j) 
(l)X X X X X
CGI-I (overall 
improvement) (j) (l)X X X X
CGI-S (upper extremity 
functional severity) (j) (l)X X X X X
CGI-I (upper extremity 
functional improvement) (j) 
(l)X X X X
PGI-S (overall severity) X X X X X
PGI-I(overall 
improvement) (l)X X X X
PGI-S (upper extremity 
functional severity)X X X X X
PGI-I(upper extremity 
functional improvement) (l)X X X X
Exit Interview (m) X X
Footnotes are on last table page.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831-1501 Page 88 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
Note: The Follow-up phone call will occur [ADDRESS_95845] report con cerning AEs. In these cases, subjects 
will be brought back into the clinic for re-evaluation at the investigator’s discretion.(a) On Day 1 (Visit 3), subjects will complete all efficacy and sa fety baseline assessment before dosing. After all baseline ass essment and procedures, subjects will 
be dosed in the clinic and will remain in the clinic for approx imately 3 to 4 hours after dosing. During this time, subjects wi ll be observed or monitored by [CONTACT_87855]. Vital signs/AEs should be taken twice during this time, one around [ADDRESS_95846] information cards. They will be allowed to take a break for lunch  
in the vicinity of the clinic, if necessary. Prior to going to the hotel, vital signs will be recorded and all AEs recorded. A responsible clinician will review AEs and 
vital signs before sending the patients to hotels/homes. (b) Clinical laboratory samples will be collected under nonfasting conditions.(c) Urine test only except at Screening and Safety Follow-up/ET visit.(d) Specific instructions: Subjects will be instructed to take 3 tablets by [CONTACT_87856] a day in the fasted condition (at l east 1 h before or after a meal) or with a 
light meal (less than 600 calories total with <30% from fat). (e) On Day 84, subjects will only get the morning dose as their last dose.(f) Interim phone calls will be conducted on Day 2, approximately at end of Week 1 and at the midpoints between Visits 4 and 5 and Visits 5 and 6. Subjects will be 
asked how they are doing and whether they are taking the drugs BID as directed. Reported AEs and concomitant medications will b e captured in the source 
documents and eCRF. All questions will be addressed.(g) 
(h) Blood samples for the determination of concentrations of TAK-831 will be collected as shown below in the Schedule of Sample s. One blood sample will be 
collected for subjects at the early termination visit. The sampling schedule may change based on emerging data but will not exc eed the number of planned samples 
(N=10). (i) Blood samples for PD will be collected immediately following the first PK sample collection for each visit a PD sample is t o be collected per the Schedule of 
Samples.(j) The efficacy assessments should be conducted by [CONTACT_87857] a particular subject , as much as possible. 
(k) The 9-HPT assessment consists of [ADDRESS_95847] 1 hour in between the 2 sets of 9-HPT assessments. (l) Sequence and timing of assessments will consider patient fatigue. The first set of 9-HPT and digital speech should be condu cted first. In addition, during 
treatment period, subjects will be taking the drugs at home/hotel. This will be followed by [CONTACT_87858]/procedures. Timing of efficacy assessments should also 
be taken into consideration. During the treatment period (Vis its 4-7), 9-HPT and digital speech should be assessed approximately  2-[ADDRESS_95848] morning 
dose which the subjects takes at home/hotel and the collection of blood sample can be the first procedure on that day.(m) A semistructured subject Exit Interview will be conducted by [CONTACT_1382] [ADDRESS_95849] dose of study medication of the Double-Blind Treatment Period 
or within 7 days of notification of termination for the Early Termination Visit.
Property of [COMPANY_005]: For non-commercial us ly and subject to the applicable Terms of Usele
concerninoncern
eline asseine ass
jects will cts will
1 to 2 houto 2 h
on cards. Tn cards
Es recordEs recor
ay in the fin the f
nd at the d at th
Reported Reporte
ill be col
dule may le ma
g the firstthe fir
ame adminme adm
ant hand, t hand
ntss.
der patienpatie
gs at homs at h
ment perioent per
2 to 6 houto 6 h
hotel andhotel an
nterview wrview
f terminaterminCCI
TAK-831
Study No. TAK-831-1501 Page 89 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
Schedule of Samples
VisitVisit 1 
(Screening) Visit 2 Visit 3 Visit 4 Visit 5 Visit 6Early 
Termination 
Visit
Day(s) -28 to -2 -1 114
(±3)49
(±3)84
(±2)
Clinical laboratory samples X X X X
PK blood collection Predose 0.[ADDRESS_95850] 
morning doseAt the end of the 
visit >4 hours after 
morning doseAt the end of the visit 
>4 hours after 
morning doseX
PD blood collection (D-
and L-serine)Predose 1-[ADDRESS_95851] 
morning doseAt the end of the 
visit >4 hours after 
morning doseAt the end of the visit 
>4 hours after 
morning doseX
Property of [COMPANY_005]: For non-commercial use only and su t to the applicable Terms of Usele
lic
ap
9
(±3)(±3)he
tt o
oseseAt
vsu
hours posours po
morning dorningan
eoCCI
TAK -[ADDRESS_95852] igators by  [CONTACT_45348] “Statement of Invest igator” (Form FDA 1572), whi ch must be com pleted and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by [CONTACT_2960] a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study -related procedures, including study -specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on p otent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authorit ies.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval o f the study and any changes by [CONTACT_4215]/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and local regulatory  requi rements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Pr omptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within [ADDRESS_95853]’s medical chart. Valid informed c onsent is the most current 
versio n approved by [CONTACT_1201]/IEC. Each informed consent form should contain a subject 
authori zation Section that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that w ill take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representa tive.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospi[INVESTIGATOR_1097], laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by [CONTACT_45349]. The invest igator should 
contact [CONTACT_4182] m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by [CONTACT_4216] -specified essent ial 
docum ents.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 91of 114
Protocol Incorporating Amendment No. 01 06October 2017
11.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95854]:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assig nment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  [CONTACT_2960] a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15.For resea rch invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The an ticipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact [CONTACT_39831] 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-[ADDRESS_95855]’s 
legally acceptable representative may discontinue  participation at any time without penalty or 
loss of benefits to which the subject is otherwise entitled.
20. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by [CONTACT_423].
21. A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely manner if information becomes availab le that may be relevant to the subject’s 
willingness to continue participation in the study.
22.
23. The foreseeable circumstances or reasons under which the subject’s participation in the study 
may be terminated.
24. A written subject authorization (either contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health information) for 
purposes of conducting the study. The subject authorization must contain the following 
statements regarding the uses and disclosures of the subject’s personal information:
a) that personal information (including personal health information) may be processed by [CONTACT_87859], including, without limitation, to the following: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assisting [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, [COMPANY_005] will make every effort to k eep your personal information confidential, 
and your name [CONTACT_87873] [CONTACT_2371];
c) that personal information (including personal health information) may be added to 
[COMPANY_005]’s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safety and effectiveness of the study drug(s), studying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon wit hdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; andProperty of [COMPANY_005]: For non-commercial use only and subject pplicable Terms of Useor r 
ures for es for 
will be inwill be 
o the subthe s
ubject’s pject
n the infthe in
he contemcont
n (includ(inclu
t authoriautho
res of es of thth
ng persong per
her counher cou
limitatlimita io
siness paness p
y agencieagency
ersonal irsonal
ransferrensfer
same levame l
[COMPANY_005] wakeda
r [CONTACT_2300] [CONTACT_2300]
t personperso
[COMPANY_005]’akeda
safetsafet
devdCCI
TAK -831
Study No. TAK -831-1501 Page 94of 114
Protocol Incorporating Amendment No. 01 06October 2017
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active m ust use highly  effec tive contraception (as defined in the informed 
consent) from Screening throughout the duration of the study , and for [ADDRESS_95856] ive contraceptio n (as defined in the i nformed consent) 
from signing the informed consent throughout the duration of the study , and for [ADDRESS_95857] the cho ice to receive unblinded treatment information.
27.A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -[ADDRESS_95858] igator’s personal 
inform ation may be transferred to othe r parti es located in countri es throughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assist ing [COMPANY_005], its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  [CONTACT_39833]:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissi on of regul atory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications use d in other clinical studies that may contain 
the sam e chemical com pound present in the study  drug.
Inspect ions and invest igations by [CONTACT_4218].
Self-inspect ion and internal audit within [COMPANY_005], its affiliates, and licensi ng partners.
Archiving and audit of study  records.
Posting investigator site contact [CONTACT_4203], study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by [CONTACT_87860] p arties for the purposes described above.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 96of 114
Protocol Incorporating Amendment No. 01 06October 2017
Appendix EDetailed Description of Amendments to Text
The primary  sections of the protocol affected by [CONTACT_39835]. 01 are indicated. 
The corresponding text has been re vised throughout the protocol.
Change 1: Revisio n of studyprocedures (reduce the number of visit s and blood draws, and update 
the randomization scheme) .
The primary changes occur in Section 6.1Study Design .
Initial 
wording:...
The study  will include a Screening Period (Day s -28 to -2), a Training Period to 
minimize practice effect on efficacy  assessment (Day  -1), treatm ent (Days 1 to 84), 
a follow-up clinic visit (~1-[ADDRESS_95859] administration of study  drug), and a 
subject Exit Interview (conducted over the phone wit hin [ADDRESS_95860] dose of 
study  medicat ion of the Double -Blind Treatm ent Peri od or wi thin 7 days of 
notification o fterminat ion for the Early Terminat ion Visit) will be based on the last 
visit of the last subject. In addit ion, several interim phone calls will also be 
conducted.
Approximately  65 subjects who m eet the study  criteria during Screening will be 
invited to at tend training to minimize practice effects on performance -based 
efficacy assessments on Day -1. On Day 1, subjects who continue to meet inclusio n 
and none of the exclusio n criteria will be rando mized in a 2:1:2 ratio to TAK -831 
high dose, TAK -831 l ow dose, or placebo, respectively. (If the rate of early  
withdrawal is substantially greater than predicted, then an increase to the number of 
rando mized subjects may be considered.) Rando mization will be stratified by 
[CONTACT_87819] (ambulatory  vs. nonambulato ry).The first 5 subjects will be 
rando mized to either placebo or TAK -831 low dose in a 2:3 ratio; the randomizat ion 
ratio for the rem aining 60 subjects will be adjusted to approximate a 2:1:2 ratio 
overall.
The study  will be conducted in approximately 4 or more specialized academic 
neuro logical clinical  centers in the [LOCATION_002] wit h expertise in, and access to, 
patients wi th FRDA.
Subjects will receive twice daily  (BID) study  drug dosing or pl acebo from  Day  [ADDRESS_95861] ions, and laboratory  tests will be conducted at specific time po ints per the 
schedule of study  procedures ( Appendix A). A follow -up safet y assessment visit 
will be conducted and a separate semistructured subject Exit Interview will be 
conducted by  [CONTACT_87820] -depth, qualita tive evaluat ion of the subject 
experience and subject -perceived change due to treatment ( Table 6.a). 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 97of 114
Protocol Incorporating Amendment No. 01 06October 2017
Amended or 
new wording :...
The study  will include a Screening Period (Day s -28 to -2), a Training Period to 
minimize practice effect on efficacy  assessment (Day  -1), treatm ent(Days 1 to 84), 
a follow-up clinic visit (~[ADDRESS_95862] administration of study  drug), and a 
subject phone Exit I nterview ( conducted over the phone within [ADDRESS_95863] 
dose of study  medicat ion of the Double -Blind Treatm ent Peri od or wi thin 7 days of 
notification o f terminat ion for the E arly Terminat ion Visit ) will be based on the last 
visit of the last subjec t. In addi tion, several  interim phone calls will also be 
conducted. and a Safety Follow -up Phone Call ([ADDRESS_95864] dose of 
study drug).
Approximately  65 subjects who m eet the study  criteria during Screening will be 
invited to attend training to minimize practice effects on performance -based 
efficacy assessments on Day -1. On Day 1, subjects who continue to meet inclusio n 
and none of the exclusio n criteria will be rando mized in a 2:1:[ADDRESS_95865] acebo, res pectively. (If the rate of early  
withdrawal is substantially greater than predicted, then an increase to the number of 
rando mized subjects may be considered.) Rando mization will be stratified by 
[CONTACT_87819] (ambulatory  vs. nonambulatory ).The first 5 subjects will be 
rando mized to either placebo or TAK -831 low dose in a 2:3 ratio; the randomizat ion 
ratio for the rem aining 60 subjects will be adjusted to approximate a 2:1:2 ratio 
overall.
The study  will be conducted in approximately 46or more speci alized academic 
neuro logical clinical  centers in the [LOCATION_002] wit h expertise in, and access to, 
patients wi th FRDA.
Subjects will receive twice daily  (BID) study  drug dosing or pl acebo from  Day  [ADDRESS_95866] ions, and laboratory  tests will be conducted at specific time po ints per the 
schedule of study  procedures ( Appendix A). A follow-up safet y assessment visit 
will be conducted and a separate semistructured subject Exit Intervi ew will be 
conducted by  [CONTACT_87820] -depth, qualitative evaluat ion of the subject 
experience and subject -perceived change due to treatment , and a Safety Follow -up 
Phone Call will be conducted (Table 6.a). 
The following sect ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Table 6.a Schemat ic of Study  Design .
Figure 6.aSchemat ic of Study  Design .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 98of 114
Protocol Incorporating Amendment No. 01 06October 2017
5.2.2 Secondary Endpoints
5.2.4 Exploratory  Endpo ints
Appendix A Schedule of Study  Procedures .
Rationale for change :To reduce patient burden by [CONTACT_87861] [ADDRESS_95867] the libert y to invite the subjects for an in person clinic al visit if concerning 
AE is reported, thus better balance the patient burden and evaluat ion of tolerabili tyand safet y. 
Addit ional safet y and tol erabilit y study  data support the testing of the compound in the FRDA 
popul ation and rando mizat ion across the hig h dose and low dose groups .
Change 2Revisio n of TAK -831 dose .
The pr imary change soccur in Section 6.2.2 Justification of Dose :
Initial 
wording:6.2.2 Justification of Dose
The doses of TAK -831 (200 m g BID and 20 mg BID) selected for the current study 
are based on PK data fro m the SRD/MRD study  (TAK -831- 1001) and brain target 
occupancy  data f rom the PET study  (TAK -
831-1003), and safet y data from  both 
clinical studies after oral administration of TAK -831 (su spensio n) in healt hy 
subjects. Preliminary PK/PD modeling analyses showed that the high dose regimen 
resul ted in steady -state exposures associated with peak target occupancy o f >90%, 
while the low dose regimen produced daily  exposures associ ated wi th peak target 
occupancy  of >50%. These 2 doses may allow characterizat ion of an 
exposure -response relat ionship wi th PD or efficacy  measures in adul t subjects wi th 
FRDA. Of note, the study drug will be administered as a tablet, which exhibits lower 
oral bioavailab ility and higher variabilit y relative to the oral suspensio n. Nutritional 
drinks (Ensure Plus) are proposed to be used in this rare disease populat ion which 
may have difficult y with swall owing. It i s ant icipated that TAK -[ADDRESS_95868] 
of food (a nutri tional drink) on the PK of a T2 tablet formulat ion of TAK -831 in 
healt hy subjects (TAK -831- 1004) i s currently planned to ensure the projected 
TAK -831 steady -state exposures can be ach ieved for optimal target occupancy, 
while remaining wit hin the range of those observed at doses up to 400 mg daily 
dose, whi ch were found to be safe.
Amended or 
new wording:6.2.2 Justification of Dose
The doses of TAK -831 ( 200 mg BID 300 and 2075 mg BID ) selected for the current 
study  are based on PK data from the SRD/MRD study  (TAK -831- 1001) and brain 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 99of 114
Protocol Incorporating Amendment No. 01 06October 2017
target occupancy data from the PET study  (TAK -831-1003), PK and food effect 
study (TAK -831- 1004), CSF D -serine study (TAK -831- 1005), and safet y data 
from bothallclinical studi es after oral  administration of TAK -831 (suspensio n) in 
healt hy subjects. Preliminary  PK/PD m odeling analyses showed that the high dose 
regimen resulted in steady -state exposures associated with peak target occupancy o f 
>90%, while th e low dose regimen produced daily exposures associated with peak 
target occupancy of >50% . These [ADDRESS_95869] 
3-fold exposure difference from the high dose to understand the relationship 
between TAK -831 and response relatio nship. In addition, CSF D- serine levels 
at 600 mg QD using T2 tablet and 800 mg suspension produced similar level of 
CSF D -serine, suggesting that 600 mg QD produced levels of D -serine 
approaching maximal DAO inhibition in the brain. These 2 doses (300 mg BID 
and 75 mg BID) may allow characterizat ion of an exposure -response relat ionship 
with PD or efficacy  measures in adult subjects with FRDA. Of note, the study  drug 
will be administered as a tablet, which exhibit s lower oral bioavailabilit y and higher 
variability relative to the oral  suspensi on. Nutri tional drinks (Ensure Pl us) are 
proposed to be used in this rare disease populat ion which may have difficult y with 
swallowing. It is anticipated that TAK -[ADDRESS_95870] of food (a nutrit ional 
drink) on the PK of a T2 tablet formulat ion of TAK -831 in healt hy subjects 
(TAK -831- 1004) i s current ly planned to ensure the projected TAK -831 steady -state 
exposures can be achieved for optimal tar get occupancy, while remaining within the 
range of those observed at doses up to 400 mg daily  dose, which were found to be 
safe. Subjects will be instructed to take 3 tablets by [CONTACT_87856] a day in 
the fasted condition (at least 1 h before or after a meal) or with a light meal 
(less than 600 calories total with <30% from fat) .This will keep the TAK -[ADDRESS_95871] ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Secti on [IP_ADDRESS] Study  Drug .
Secti on [IP_ADDRESS] Sponsor -supplied Drug .
Table 8.a Dose and Regimen .
Secti on
 8.2Study  Drug Assignment a nd Dispensing Procedures .
Section 8.6Accountabilit y and Destructi on of  Sponsor -Supplied Drugs .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK -831
Study No. TAK -831-1501 Page 100of 114
Protocol Incorporating Amendment No. 01 06October 2017
Rationale for change :Addit ional clinic al studi es in heal thy volunteers and understanding CSF 
D-serine levels in relat ionship wit hTAK -[ADDRESS_95872] 3- fold exposure difference from the high dose 
to understand the relationship between TAK-831 PK and response .
Change 3: Recatagorizing of object ives and endpoints related to Activit ies of Daily Living.
The primary  change soccur in Section 5.1Object ivesand Sect ion 5.2Endpoints :
Initial 
wording:5.1.[ADDRESS_95873] ive of the study  is to evaluate the efficacy of TAK -831 
versus placebo on Activities of Daily Living (ADL), as measured by [CONTACT_87862] (FARS ).
5.1.3 Other Secondary Objectives
The seconda ry objectives of the study  are:
...
5.2.2 . Key Secondary Endpoint
The key  secondary  endpoint for this study  is the change fro m Baseline to Week 12 
on the ADL co mponent of the FARS after treatment with TAK -831, co mpared with 
placebo.
5.2.3 Other Secondary Endpoints
....
The change from Baseline to Day 2, Weeks 2 and 7 on the 9-HPT after treatment 
with TAK -831, com pared wi th placebo.
The change from Baseline to Weeks 2 and 7 on the ADL individual items after 
treatm ent wi th TAK -831, com pared wi th placebo.
....
5.2.4 Exploratory Endpoints
....
Amended or 
new wording:5.1.2 Key Secondary Objective Objectives
The key  secondary  object ive of the study  is toToevaluate the efficacy of 
TAK -831 versus placebo on Activities of Daily  Living (ADL), as measured by  
[CONTACT_87863] (FARS ), and those 
items that related to upper limb function.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831- 1501 Page 101 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
5.1.3 Other Secondary Objectives
The secondary objectives of the study are.
...
5.2.2. Key Secondary Endpoint Endpoints
!The key secondary endpoint for this study is the change from Baseline to Week 
12 on the ADL component of the FARS after treatment with TAK-831, 
compared with placebo.
5.2.3 Other Secondary Endpoints
Other secondary endpoints for this study as follows:
!The change from Baseline to Day 2, Weeks 2 and 7 on the 9-HPT Weeks 2, 7, 
and 12 on the ADL component upper limb function items (ADL items 3 to 
5) of the FARS , after treatment with TAK-831, compared with placebo. 
!The change from Baseline to Weeks 2 and 7 on the 9-HPT-1after treatment 
with TAK-831, compared with placebo.
!The change from Baseline to Weeks 2, 7, and 12 on the ADL individual items 
after treatment with TAK-831, compared with placebo.
....
!Percentage of subjects whose 9-HPT completion time is reduced by [CONTACT_2669] 
15% and at least 20% from Baseline.
....
5.2.4 Exploratory Endpoints
....
The following sections also contain this change:
!Section  2.0 STUDY SUMMARY.
!Section  13.1 Statistical and Analytical Plans.
Rationale for change: While the ADL is important, the probability of detecting significant 
change in this study of short duration is low and therefore it is recategorized as one of the 
secondary endpoints.Property of Takedfoollollowinwied n-commercial use only and subject to the applicable Terms of Useeline to Wine to
AKAK--831,[ADDRESS_95874] 20% 20%
loratoryorator
SectiSect
!!Sed
yCCI
TAK -831
Study No. TAK -831-1501 Page 102of 114
Protocol Incorporating Amendment No. 01 06October 2017
Change 4: Clarificat ion of endpo ints related to the [ADDRESS_95875].
The primary  change soccur in Secti on 5.2Endpoints :
Initial 
wording:5.2.1 Primary Endpoint
The primary  endpoint for thi s study  is the change from  Baseline to Week 12 in the 
time (in seconds) to complete the 9 -HPT after treatment with TAK -831, com pared 
with placebo.
...
5.2.3 Other Secondary Endpoints
Other secondary endpoints for this study as fo llows:
The change from Baseline to Day 2, Weeks 2 and 7 on the 9-HPT after treatment 
with TAK -831, com pared wi th placebo.
...
5.2.5 Exploratory Endpoints
Exploratory  endpo ints for thi s study  as fo llows:
...
Amended or 
new wording:5.2.1 Primary Endpoint
The primary  endpoint for thi s study  is the change from  Baseline to Week 12 in the 
inverse of the time (in seconds) to com plete the 9 -HPT (9-HPT-1)after treatm ent 
with TAK -831, com pared wi th placebo.
...
5.2.32Other Secondary Endpoints
Other secondary endpoints for this study as fo llows:
The change from Baseline to Day 2, Weeks 2 and 7 on the 9 -HPT-1after 
treatm ent wi th TAK -831, com pared wi th placebo.
...
Percentage of subjects whose 9- HPT completion time is reduced by [CONTACT_2669] 
15% and at least 20% from Baseline.
...
5.2.54Exploratory Endpoints
Exploratory  endpo ints for thi s study  as fo llows:
...
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use

TAK-831
Study No. TAK-831- 1501 Page 103 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
The following sections also contain this change:
Section  2.0 STUDY SUMMARY.
Rationale for change: To clarify d etails on e ndpoints.
Change  5: Revision and clarification of study entry criteria.
The primary changes occur in Section  7.1 Inclusion Criteria and Section  7.2 Exclusion Criteria:
Initial 
wording:7.[ADDRESS_95876] eligibility is determined according to the following criteria prior to entry 
into the study: 
1. In the opi[INVESTIGATOR_871], the subject is capable of understanding and 
complying with protocol requirements.
2. The subject signs and dates a written, informed consent. If written consent is not 
possible due to physical incapacity, written consent on behalf of the participant 
will be sought from the participant’s relatives or caregivers (or from a legally 
acceptable representative).
...
7.[ADDRESS_95877] has uncontrolled, clinically significant neurologic, cardiovascular, 
pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease 
(including uncontrolled diabetes) or other abnormality (other than the disease 
being studied), which may impact the ability of the subject to participate or 
potentially c onfound the efficacy and safety evaluation. The subject has medical 
history or conditions that, in the opi[INVESTIGATOR_871], may interfere with 
study conduct or clinical assessments.
...
5. The subject has a history of cancer, except basal cell carcinoma or in situ 
cervical cancer that has been in remission for ≥[ADDRESS_95878] been infected with human 
immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus. Property of [COMPANY_005]: For no(inon-commercial use only and subject to te followifollow
subject ubjec
entsnts.
written, iritten
apacitpacit y
partiarticipacip
tive).ve).
iteriaeria
ubject hject b
lmomonaryna
ncludinclud
beingbe
poo the applicable Te of UseTe
ca
pp
nn7.27.2ExEe
otCCI
TAK -[ADDRESS_95879] has a posit ive urine drug result for drugs of abuse (defined as any 
illicit drug use without a valid prescription or medical need) at Screening.
...
9. The subject has a history of drug abuse (defined as any illicit drug use) or a history 
of alcoho l abuse (defined as regular consumpt ion of 3 or more units per day on 1 
occasi on per week or 7 or more uni ts in any  given week) wi thin [ADDRESS_95880] posit ive answers on item 4 or 5 on the 
Columbia Suici de Severi ty Rating Scal e (C-SSRS, life -time versio n) at 
Screening or Day  1.
...
17. The subject has 1 or more laboratory  values outside the normal range that are 
consid ered by [CONTACT_87864] ; 
or the subject has any of the fo llowing at the Screening Visit: a serum creat inine 
value >1.[ADDRESS_95881] . Atotal serum  total  bilirubin val ue >1.5 ×ULN . A
serum  ALT or AST valu e >2×ULN , or prol actin ≥100 ng/mL.
Amended or 
new wording:7.[ADDRESS_95882] eligibilit y is determined according to the following criteria prior to entry  
into the study : 
1. In the opi[INVESTIGATOR_1649] o f the invest igator, the subject is capable of understanding the 
informed consent, and capable o f understanding and co mplying with protocol 
requi rements .
2. The subject signs and dates a written, informed consent. If written consent is not 
possible due to physical incapacit y, written consen t on behalf o f the parti cipant 
will be sought fro m the parti cipant's relatives or caregivers (or from a legally  
acceptable representative). 
...
7.2Exclusion Criteria
...
2.The subject has , based on medical history and judgment of the investigator,
uncontrol led, clinically significant neurologic, cardiovascular, pulmo nary, 
hepat ic, renal, metabo lic, gastrointest inal, or endocrine disease (including 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -831
Study No. TAK -831-1501 Page 105of 114
Protocol Incorporating Amendment No. 01 06October 2017
uncontrolled diabetes) or other abnormalit y (other than the disease being 
studi ed), which may impact the abilit yof the subject to participate or potentially 
confound the efficacy  and safet y evaluat ion. The subject has medical history  or 
condi tions that, in the opi[INVESTIGATOR_1649] o f the invest igator, may interfere with study  
conduct or clinical assessments.
...
5.The subject has a history  of cancer, except squamous cell carcinoma or basal 
cell carcino mathat have been treated or excised, or in sit u cervical cancer that  
has been in remissio n for ≥[ADDRESS_95883] a history of having been 
infected with human immunodeficiency virus (HIV), hepatit is B virus, or 
hepat itis C virus.
7.The subject has a Urine drug screen positive urine drug result for drugs of 
abuse (defined as any  illici tatscreening or, except for a prescribed drug use 
without a valid prescript ion or m edical need) allowed by [CONTACT_87865]. Cannabinoid use is not permitted either recreationally or 
medically. 
...
9. The subject has a history of drug abuse (defined as any illicit drug use) or a history 
of alcoho l abuse (defined as regular consumpt ion of 3 or more units per day on 1 
occasi on per week or 7 or more uni ts in any  given week) wi thin [ADDRESS_95884] posit ive answers on item 4 or 5 on the 
Columbia Suici de Severi ty Rating Scal e (C-SSRS, life -time versio n)at 
Screening or Day  1.
...
17. The subject has 1 or more laboratory  values outside the normal range tha t are 
considered by [CONTACT_87864] ; 
or the subject has any of the fo llowing at the Screening Visit: a serum creat inine 
value >1.[ADDRESS_95885] . A, atotal serum total bilirubin value >1.5 ×ULN . Aor 
a serum ALT or AST value >2 ×ULN , or prol actin ≥100 ng/mL .
18. The subject has current history of symptomatic orthostatic hypotension.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_95886] ions also contain this change:
Secti on 2.0STUDY SUMMARY .
Rationale for change: To cl arify study  entrance cri teria.In addition, squam ous cell  carcino mas
with excisi on that have been treated or excised are added to the except ions of exclusio n. To 
reduced patient risk of falling, subjects with current history  of symptom atic orthostatic 
hypotension are excluded.
Change 6: Clarificat ion of excluded medicat ions and products.
The primary  change s occur in Section 7.3Excluded Medicat ions, Supplements, and Dietary  
Products and Section 7.4Diet, Fl uid, Activit y Control :
Initial 
wording:Section 7.3 Excluded Medications , Supplements, and Dietary Products
...
Table 7.a Excluded/Allowed Medications and Treatments.
Psychotropi c agents not otherwise specified (including st imulants, try ptophan, 
melatonin and dopamine agonists)
Herbal remedies, which are psychoactive (eg, St. John's Wort, kava kava, 
valerian, ginkgo bilo ba, m elatonin)
Muscle relaxants
Antiparkinson drugs
Section 7.4 Diet, Fluid, Activity Control
Subjects will maintain their regular routine o f exercise and physical therapy or 
speech therapy .
Alcoho l intake will be restricted to no more than 1 unit in 1 occasion and less than 3 
units per week. One unit is equivalent to a half -pi[INVESTIGATOR_87779] 1 single measure of 
spi[INVESTIGATOR_87780] 1 sm all glass of wine.
Amended or 
new wording:Section 7.3 Excluded Medications, Supplements , and Dietary Products
...
Table 7.a Excluded/Allowed Medications and Treatments.
Psychotropi c agents not otherwise specified (including but not limited to
stimulants, try ptophan, m elatonin and dopamine agoni sts)
Herbal remedies, which are psychoactive (eg, St. John's Wort, kava kava, 
valerian, ginkgo bilo ba, m elatonin ), OTC (e.g., cough syrup)
Muscle relaxants including but not limited to baclofen, tizanidine, 4 
aminopyridine
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -831
Study No. TAK -831-1501 Page 107of 114
Protocol Incorporating Amendment No. 01 06October 2017
Antiparkinson dr ugsAntiparkinsonian drugs including dopamine agonists
Section 7.[ADDRESS_95887] of any clinical assessments.
Rationale for change :To cl arify excluded m edicati ons and products.
Change 7: Revisio n of statistical  analysis .
The primary  change s occur in Section 13.1.[ADDRESS_95888] ics and Secti on [IP_ADDRESS] Primary  Efficacy  Analysis
Initial 
wording:13.1.[ADDRESS_95889] ics including age, gender, race, BMI, and 
medical history  will be listed and summarized by [CONTACT_87866].
Baseline values for efficacy assessments will also be summarized by [CONTACT_87867] .
....
[IP_ADDRESS] Primary Efficacy  Analysis
The primary  endpoint to be measured is the change fro m Baseline in the t ime (in 
seconds) to com plete the 9 -HPT at 12 weeks . An inverse transform will be used to 
reduce skewness. The primary efficacy  comparison will be the comparison between
TAK -831 andplacebo in change fro m Baseline in the t ime to complete the 9 -HPT at 
12 weeks.
....
[IP_ADDRESS] Secondary  Efficacy  Analysis
Analysis of secondary  efficacy  endpoints will  be based on the FAS. For t hese 
endpo ints,which are continuous change fro m Baseline endpo ints, comparisons 
between TAK -831 and placebo will be based on similar methodology  to that 
described for the primary  efficacy analysis. However, for the CGI -I and PGI -I 
endpo ints the correspond ing Baseline severit y scores (CGI -S or PGI -S, 
respectively ) will be used as the Baseline covariate in the MMRM and analysis o f 
covari ance models. For each secondary endpoint, the 1- sided al ternat ive hypothesis 
is that TAK- 831 is superior to placebo in the clinic ally favorable di rection, for 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -831
Study No. TAK -831-1501 Page 108of 114
Protocol Incorporating Amendment No. 01 06October 2017
example, a lower mean score on the FARS ADL scale.
Amended or 
new wording:13.1.[ADDRESS_95890] ics including age, gender, race, BMI, a nd 
medical history  will be listed and summarized by [CONTACT_87866]. the FAS . 
Baseline values for efficacy assessments will also be summarized by [CONTACT_87868] .
....
[IP_ADDRESS] Primary Efficacy Analysis
The primary  endpoint to be measured for this study is the change fro m Baseline to 
Week 12 in the inverse of the time (in seconds) to complete the 9 -HPT at 12 weeks . 
An inverse transform will be used to reduce skewness. The primary efficacy 
comparison will  be the com parison between (9-HPT-1) after treatment with
TAK -831 and, compared with placebo in change fro m Baseline in the time to 
complete the 9 -HPT at 12 weeks .
....
[IP_ADDRESS] Secondary  Efficacy  Analysi s
Analysis of secondary  efficacy  endpoints will  be based on the FAS. For these 
endpo ints which are continuous change from Baseline endpo ints, comparisons 
between TAK -831 and placebo will be based on similar methodology  to that 
described for the primary  effic acy analysis. However, for the CGI -I and PGI -I 
endpo ints the corresponding Baseline severit y scores (CGI -S or PGI -S, 
respectively ) will be used as the Baseline covariate in the MMRM and analysis o f 
covari ance models.For binary or ordinal endpoints, Cochran -Mantel -Haenszel 
tests will be used with ambulation status at randomization as a stratification 
factor. For binary or ordinal endpoints, missing data will be imputed as no 
change from Baseline. For each secondary  endpoint, the 1 -sided al ternat ive 
hypothesi s is that TAK -831 is superior to placebo in the clinically favorable 
direction, for example, a lower mean score on the FARS ADL scale.
Rationale for change :To update statist ical analysis .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -831
Study No. TAK -831-1501 Page 109of 114
Protocol Incorporating Amendment No. 01 06October 2017
Change 8: Inclusio n of the summary o f clinical data from Studies TAK -831-1004 and 
TAK -831-1005.
The primary  change s occur in Section 4.1.4 Clinic al Background.
Initial 
wording:4.1.[ADDRESS_95891] been conducted in healt hy subjects: a 
first-in-human study  to determine the pharmacokinetic (PK) profiles of TAK -831 
oral suspensi on after single -rising dose (SRD) and mult iple-rising dose (MRD) 
administration, as well as the relat ive bioavai labilit y and effect of food on the PK of 
the T1 tablet formulat ion of TAK-831 (TAK -831- 1001); and a study to demonstrate 
DAO target engagement in the brain as measured by [CONTACT_87869] n tom ography 
(PET) (TAK-831- 1003). Pl asma D -serine levels, TAK -831 pl asma concentrati ons 
and safet y were al so evaluated. There is an ongoing clinical study , TAK -
831-1004, 
to study  the food (nutrit ional drink) effect of T2 tablet formulation.
...
4.3 Benefit/Risk Profile 
The literature suggests that D -serine is a crit ical mediator of gl utam ate receptor –
dependent funct ions of the cerebellum [2].As a DAO inhibitor that increases 
D-serine in the cerebellum, TAK -831 has the potent ial to increase 
NMDA -dependent glutamatergic signaling. One disease state that could be treated 
through this mechanism is FRDA. TAK -831 showed efficacy  in a m ouse m odel of 
FRDA wit h single doses and dosed daily for 15 days at 3 mg/kg. 
...
The proposed phase [ADDRESS_95892]/MRD study  (TAK -831- 1001), brain target occupancy  data from  the 
PET study  (TAK -
831-1003), and safet y data from  both clinical studies after oral 
administration of TAK -831 (suspension) in healt hy subjects as a single dose up to 
750 mg (TAK -
831-1001 and TAK - 831-1003) or for 13 days as a mult iple dose up to 
400 m g/day (TAK -831-1001). The dose and study  durati on of  TAK -[ADDRESS_95893] ion of TAK -831, nonclinical data, and the 2 phase 1 studies 
conducted to date. These procedures may be modified during the study if necessar y 
based on evaluat ion of any  addi tional clinical or nonclinical safet y data.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -831
Study No. TAK -831-1501 Page 110of 114
Protocol Incorporating Amendment No. 01 06October 2017
...
•Postural hypo tension and dizziness were observed in prior studies in healt hy 
subjects, although the incidence for subjects treated with TAK -[ADDRESS_95894] ion, 
and thus are suscept ible to fall, s ubjects shoul d be carefully  monitored f or 
possible orthostatic hypotensive effects of TAK -831 administration. 
Addit ionally , subjects shoul d be instructed to take appropriate precautionary  
measures to prevent falling while under treatment with TAK -831.
...
Amended or 
new wording:4.1.[ADDRESS_95895] been conducted in healthy subjects: a 
first-in-human study  to determine the pharmacokinetic (PK) profiles of TAK -831 
oral suspensi on after single -rising dose (SRD) an d mult iple-rising dose (MRD) 
administration, as well as the relat ive bioavailabilit y and effect of food on the PK of 
the T1 tablet formulat ion of TAK-831 (TAK -831- 1001); and a study to demonstrate 
DAO target engagement in the brain as measured by [CONTACT_87869] n tom ography 
(PET) (TAK-831- 1003). Pl asma D -serine levels, TAK -831 pl asma concentrati ons 
and safet y were al so evaluated. There is an ongoing clinical study, TAK -
831-1004, 
to study  the food (nutrit ional drink) effect of T2 tablet formulation. Since th ese 
studies were conducted, a single dose PK and food -effect, bioavailability study 
with the T2 tablet formulation (TAK -831- 1004) has completed active dosing, 
and a study examining additional escalating multiple doses of TAK -831 higher 
than those achieved in the TAK -831-1001 study was initiated and is ongoing 
(TAK -831-1005).
...
TAK -831- [ADDRESS_95896] met criteria for orthostatic hypotension at a single time 
point without an accompanying report of a dizziness AE. There were no 
concerning trends in laboratory, ECG, or vital sign data . TAK -831 given as T2 
tablet coadministered with the nutritional drink (Ensure Plus) increased mean 
Cmaxand AUC ∞values by 35% and 21%, respectively. Treatment with a single 
oral dose of 400mg TAK -831 T2 formulation temporally increased plasma 
concentration of D- serine, similar to the results obtained in the Study 
TAK -831- 1001. The magnitude and kinetics of the chan ge in plasma D -serine 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_95897] blinded, sponsor 
unblinded, placebo
-controlled clinical study progressively assessing 
independent cohorts of he althy subjects to continue evaluation of the safety, 
tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of 
escalating multiple doses of TAK -[ADDRESS_95898] to change upon finalization following study monitoring, 
source data veri fication, and discrepancy query management prior to 
database lock. At this time, two cohorts with 8 subjects each (6 TAK -831 and 2 
placebo) have completed treatment at dose levels of 600 mg QD (T2 tablet 
formulation) or 800 mg QD (oral suspension) administ ered first as a single 
dose, and then administered for up to [ADDRESS_95899] common treatment -emergent 
AEs; nausea in the absence of post -lumbar puncture syndrome was reported 
by [CONTACT_87870]. All epi[INVESTIGATOR_1865] s of nausea were mild in intensity and 
self-limiting. Two subjects in each cohort met categorical criteria for 
orthostatic hypotension on at least one assessment; none of these findings were 
associated with an AE of dizziness. There were no concerning tren ds in 
laboratory, ECG, or vital sign data collected in these cohorts. 
Following once -daily dosing, mean plasma exposures of TAK -831 were higher 
(Cmax: 1.3-fold and AUC: 1.8- fold) when dosed as an oral suspension than as 
T2 tablets. Geometric mean Cmax val ues were 1466 and 1976 ng/mL with 600 
mg QD (T2 tablet formulation) and 800 mg QD (oral suspension), respectively. 
Mean steady -state exposures (AUC t) over the 24 -hour dosing interval were on 
average 4993 and 8853 ng.hr/mL for the respective [ADDRESS_95900] curve from time 0 to 24 hours of CSF D -serine for both the 
600mg T2 and 800 mg oral suspension treatment groups when compared to 
placebo; changes in CSF D -serine were noticeably higher after multip le doses 
of TAK -[ADDRESS_95901] curve for CSF D -serine 
was similar for both the 600 mg T2 and 800 mg oral suspension, suggesting 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -831
Study No. TAK -831-1501 Page 112of 114
Protocol Incorporating Amendment No. 01 06October 2017
that the maximal PD effec t in the CSF was achieved at drug exposures attained 
with the 600mg T2 dose  and 800 mg suspension
Overall, the emerging safety data from the TAK -831- 1004 and TAK -831- 1005 
studies are consistent with the data collected in prior clinical studies and do 
not alter the risk prof ile of the compound.
...
The literature suggests that D -serine is a crit ical medi ator of gl utam ate receptor –
dependent funct ions of the cerebellum and was shown to reduce ataxia in animal 
model of spi[INVESTIGATOR_87781] [2]. As a DAO inhibitor that increases D -serine in 
the cerebellum, TAK -831 has the potential to increase NMDA -dependent 
glutam atergi c signaling. One disease state that could be treated through this 
mechanism is FRDA. TAK -831 showed e fficacy in a mouse model of FRDA wit h 
single doses and dosed daily for 15 days at 3 mg/kg. 
4.3 Benefit/Risk Profile 
The proposed phase [ADDRESS_95902] been selected based on PK data 
from the SR D/MRD study studies (TAK -831-1001 and TAK - 831-1005 ), brain 
target occupancy data from the PET study  (TAK -831-1003), CSF D -serine data 
from the TAK -831- 1005 study, and safet y data from  bothallclinical studies after 
oral administration of TAK -831 (suspension) in healthy subjects as a single dose up 
to 750 mg (TAK -831- 1001 and TAK - 831-1003) or for 13 days as a mult iple dose up 
to 400 m g/day  (TAK -831- 1001). described above. The dose and study  durati on of  
TAK -[ADDRESS_95903] not resulte d in a safet y signal that woul d 
prevent addit ional studi es.in subjects with FRDA.
Potenti al risks, and ri sk mi tigation measures to be implemented in studies with 
TAK -831, are described below. These measures are based on what is known about 
the mechanism o f action of TAK -831, nonclinical data, and the 2 phase 1 studies 
conducted to date , and general considerations in the development of new 
chemical entities. These procedures may be modified during the study if necessar y 
based on evaluat ion of any  addi tional clinical or nonclinical safet y data.
...
Postural hypotensio n and dizziness were observed in prior studies in healt hy 
subjects , although . However, the incidence forof dizziness in subjects treated 
with TAK -831 and placebo was similar. In addition, 2 subje cts who received 
250 mg TAK -831 showed blood pressure variations consistent with 
orthostatic hypotension without clinical symptoms. These measurements 
were taken at the Study exit visit and were considered not -related to 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_95904] ion, 
and thus are suscept ible to fall, subjects should be carefully  monitored f or 
possible orthostatic hypotensive effects of TAK -831 administration. 
Addit ionally , subjects shoul d be instructed to take appropriate precauti onary  
measures to prevent falling while under treatment with TAK -831. Additionally, 
subjects with current history of postural hypotension will be excluded from 
the study.
Rationale for change : To provide the most current clinical data available for TAK -831.
Change 9: Engagement of a n internal  DMC to review unblinded safety  data.
The primary  change s occur in Section 11.0 STUDY -SPECIFIC COMMITTEES .
Initial 
wording:11.0 STUDY- SPECIFIC CO MMITTEES
No steering committee, data safety  monitoring commi ttee, clinical  endpoint 
committee, or adjudicat ion committee will be used in this study.
Amended or 
new wording:11.[ADDRESS_95905] not been any safety findings that 
indicate the need for an independent Data Monitoring Committee (DMC) .
However, in addition to the ongoing review of blinded safety data by [CONTACT_87871], the sponsor will
establish an internal DMC independent of the study and project team to 
periodically review unblinded safety data during conduct of this study to 
complement the routine safety monitoring approach for compounds at this 
stage of development. The functions an d procedures of the committee will be 
outlined in a DMC Charter . 
Rationale for change : To coordinate the monitoring of safety and tol erabili ty data for the 
TAK -831 compound, together with otherupcoming clinical trials in the schizophrenia populat ion .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK-831
Study No. TAK-831- 1501 Page 114 of 114
Protocol Incorporating Amendment No. 01 06 October 2017
Change  10:Personnel change
The primary changes occur in Section 1.1 and Section 1.2
Initial 
wording:Section 1.1
Section 1.2
Amended or 
new wording:Section 1.1
Section 1.2
Rationale for change: To update personnel responsibilities.[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Property of [COMPANY_005]: For non-com: To o upduco
oncial use only and subject to the applicable Terms of Usem
suubj
l use only and
ommercia
䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GHH䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢳䢼䢢䣃䢢䣒䣪䣣䣵䣧䢢䢴䢮䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴 䣱䣮䣮䣧䣦䢮䢢䣒䣣䣴䣣䣮䣮䣧䣮䢯䣃䣴䣯䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧
䣇䣨䣨䣫䣥䣣䣥䣻䢮䢢䣖䣱䣮䣧䣴䣣䣤䣫䣮䣫䣶䣻䢮䢢䣣䣰䣦䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䣏䣷䣮䣶䣫䣲䣮䣧䢢䣆䣱䣵䣧䣵䢢 䣱䣨䢢䣑䣴䣣䣮䢢䣖䣃䣍䢯䢺䢵䢳䢢䣫䣰䢢䣃䣦䣷䣮䣶䢢䣕䣷䣤䣬䣧䣥䣶䣵䢢䣙䣫䣶䣪䢢䣈䣴䣫䣧䣦䣴䣧䣫䣥䣪
䣃䣶䣣䣺䣫䣣
&OLQLFDO$SSURYDO 2FW87&
&OLQLFDO93$SSURYDO 2FW87&
%LRVWDWLVWLFV$SSURYDO 2FW87&[COMPANY_003]
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Useble Tate ate 
ablHH:mm ‘UH:mm eT
ab87&87&

2FW2FW